def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES
EXCHANGE ACT OF 1934 (Amendment
No. )
Filed by the
Registrant þ
Filed by a Party other than the
Registrant o
Check the appropriate box:
o Preliminary
Proxy Statement
o Confidential,
for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
þ Definitive
Proxy Statement
o Definitive
Additional Materials
o Soliciting
Material Pursuant to
§240.14a-12
INVERNESS MEDICAL INNOVATIONS, INC.
(Name of Registrant as Specified In
Its Charter)
(Name of Person(s) Filing Proxy
Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
þ
|
No fee required.
|
|
o
|
Fee computed on table below per Exchange Act
Rules 14a-6(i)(1)
and 0-11.
|
|
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act
Rule 0-11
(set forth the amount on which the filing fee is calculated and
state how it was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
o
|
Fee paid previously with preliminary materials.
|
|
o
|
Check box if any part of the fee is offset as provided by
Exchange Act
Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its
filing.
|
|
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
SPECIAL
MEETING OF STOCKHOLDERS
To Be Held December 20, 2007
November 20,
2007
Dear Fellow Stockholder:
You are cordially invited to attend Inverness Medical
Innovations (the Company) Special Meeting of
Stockholders on Thursday, December 20, 2007 at
11:00 a.m., local time, at our corporate headquarters
located at 51 Sawyer Road, Suite 200, Waltham, MA 02453.
The only matter scheduled to be considered at the special
meeting is a proposal to amend the Companys 2001 Stock
Option and Incentive Plan to increase the number of shares
reserved for issuance under the 2001 Stock Option and Incentive
Plan. You will have an opportunity to ask questions.
Whether or not you plan to attend the meeting in person, it is
important that your shares be represented and voted. Therefore,
after reading the enclosed proxy statement, please complete,
sign, date and return the enclosed proxy card promptly. You may
also vote by telephone, or electronically over the Internet, by
following the instructions on your proxy card.
We look forward to seeing you at the meeting. Your vote is
important to us.
Cordially,
Ron Zwanziger
Chairman, Chief Executive Officer and President
INVERNESS
MEDICAL INNOVATIONS, INC.
51 Sawyer Road, Suite 200
Waltham, Massachusetts 02453
NOTICE OF SPECIAL MEETING OF
STOCKHOLDERS
|
|
|
Date:
|
|
Thursday, December 20, 2007
|
Time:
|
|
11:00 a.m., local time
|
Place:
|
|
Inverness Medical Innovations, Inc.
|
|
|
51 Sawyer Road, Suite 200
|
|
|
Waltham, MA 02453
|
Purpose:
1. Approve an increase to the number of shares of common
stock available for issuance under the Inverness Medical
Innovations, Inc. 2001 Stock Option and Incentive Plan by
3,000,000, from 8,074,871 to 11,074,871; and
2. Conduct such other business as may properly come before
the special meeting and at any adjournment or postponement
thereof.
Only stockholders of record on November 15, 2007 may vote
at the special meeting and at any adjournment or postponement
thereof. This proxy solicitation material is being mailed to
stockholders on or about November 20, 2007.
Our Board of Directors unanimously recommends you vote
FOR each of the proposals presented to you in this
proxy statement.
Your vote is important. Please cast your vote by mail, telephone
or over the Internet by following the instructions on your proxy
card.
By Order of the Board of Directors
Jay McNamara, Esq.
Assistant Secretary
November 20, 2007
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
3
|
|
|
|
|
6
|
|
|
|
|
6
|
|
|
|
|
7
|
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
10
|
|
|
|
|
10
|
|
|
|
|
10
|
|
|
|
|
11
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
14
|
|
|
|
|
14
|
|
|
|
|
15
|
|
|
|
|
16
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
18
|
|
|
|
|
18
|
|
|
|
|
18
|
|
|
|
|
19
|
|
|
|
|
|
|
|
|
|
19
|
|
|
|
|
|
|
|
|
|
20
|
|
|
|
|
|
|
|
|
|
20
|
|
|
|
|
|
|
|
|
|
A-1
|
|
i
November 20, 2007
INVERNESS
MEDICAL INNOVATIONS, INC.
51 Sawyer Road, Suite 200
Waltham, Massachusetts 02453
This proxy statement is furnished in connection with the
solicitation of proxies by the Board of Directors of Inverness
Medical Innovations, Inc. for use at our Special Meeting of
Stockholders to be held on Thursday, December 20, 2007 at
11:00 a.m., local time, at our corporate headquarters
located at 51 Sawyer Road, Suite 200, Waltham, MA, and at
any adjournments or postponements of the special meeting.
References in this proxy statement to us,
we, our and Company refer to
Inverness Medical Innovations, Inc., except where otherwise
indicated.
Holders of our common stock, as recorded in our stock register
at the close of business on November 15, 2007, may vote at
the special meeting on matters properly presented at the
meeting. As of that date, there were 59,223,073 shares of
our common stock outstanding and entitled to one vote per share.
A list of stockholders will be available for inspection for at
least ten days prior to the meeting at the principal executive
offices of the Company at 51 Sawyer Road, Suite 200,
Waltham, MA 02453-3448.
You may vote in person at the meeting or by proxy. We recommend
you vote by proxy even if you plan to attend the meeting. You
can always change your vote at the meeting.
Most stockholders have a choice of voting by using a toll free
number, by submitting their vote over the Internet or by
completing a proxy card and mailing it in the postage-paid
envelope provided. Please refer to your proxy card or the
information forwarded by your bank, broker or other holder of
record to see which options are available to you.
Our Board of Directors (the Board) is asking for
your proxy. Giving us your proxy means you authorize us to vote
your shares at the meeting, or at any adjournment or
postponement thereof, in the manner you direct.
If you sign and return the enclosed proxy card but do not
specify how to vote, we will vote your shares in favor of
increasing the number of shares of common stock available for
issuance under the Inverness Medical Innovations, Inc. 2001
Stock Option and Incentive Plan.
As of the date hereof, we do not know of any other business that
will be presented at the meeting, except for those incident to
the conduct of the meeting. If other business shall properly
come before the meeting, or any adjournments or postponements
thereof, the persons named in the proxy will vote your shares
according to their best judgment.
In addition to this mailing, our employees may solicit proxies
personally, electronically or by telephone. We pay all of the
costs of soliciting this proxy. We also reimburse brokers,
banks, nominees and other fiduciaries for their expenses in
sending these materials to you and getting your voting
instructions. We have also engaged MacKenzie Partners, Inc. to
assist us with the solicitation of proxies, and we expect to pay
MacKenzie Partners, Inc. approximately $7,000 for its services
plus
out-of-pocket
expenses incurred during the course of its work.
You may revoke your proxy before it is voted by submitting a new
proxy with a later date, by voting in person at the meeting, or
by notifying the Companys Secretary in writing.
In order to carry on the business of the meeting, we must have a
quorum. Under our bylaws, this means at least a majority of the
voting power of all outstanding shares entitled to vote must be
represented at the meeting, either by proxy or in person.
Proxies marked as abstaining or withheld, limited proxies and
proxies containing broker non-votes with respect to any matter
to be acted upon by stockholders will be treated as present at
the meeting for purposes of determining a quorum, but will not
be counted as votes cast on such matter. A broker
non-vote is a proxy submitted by a broker or other nominee
holding shares on behalf of a client in which the broker or
other nominee indicates that it does not have discretionary
authority to vote such shares on a particular matter.
Each proposal sets forth the vote required for approval of the
matter.
Multiple
Stockholders Sharing the Same Address
Please note that brokers may deliver only one proxy statement to
multiple security holders sharing an address. This practice,
known as householding is designed to reduce printing
and postage costs. If any stockholder residing at such an
address wishes to receive a separate annual report or proxy
statement, the Company will promptly deliver a separate copy to
any stockholder upon written or oral request to Doug Guarino at
Inverness Medical Innovations, Inc., 51 Sawyer Road,
Suite 200, Waltham, MA 02453, by telephone at
(781) 647-3900 or by
e-mail at
doug.guarino@invmed.com.
2
APPROVAL
OF INCREASE IN OPTION SHARES
The Board has adopted and is seeking stockholder approval of an
amendment to the 2001 Stock Option and Incentive Plan to
increase the number of shares of common stock that are available
to be issued through grants or awards made thereunder or through
the exercise of options granted thereunder from
8,074,081 shares to 11,074,081 shares. In addition,
the 2001 Stock Option and Incentive Plan, as amended, will
provide that different types of awards will count differently
against the total number of shares available. Full value awards
settled in stock, other than an award that is a stock option or
other award that requires the grantee to purchase shares for
their fair market value at the time of grant, will be counted
against the overall share limitation as 3.0 shares. All
other awards will continue to be counted against the overall
share limitation as 1.0 share.
Of the 8,074,081 shares of common stock authorized for
issuance in connection with grants made under the 2001 Stock
Option and Incentive Plan, only 29,825 shares remained
available for future grants or awards as of November 15,
2007. While some additional shares may become available under
the 2001 Stock Option and Incentive Plan through employee
terminations, this number is expected to be inconsequential.
The Board recommends this action in order to enable the Company
to continue to provide a source of stock to attract and retain
talented personnel, especially in the event of future
acquisitions and anticipated future growth. The Board believes
that stock options promote growth and provide a meaningful
incentive to employees of successful companies.
The increase of 3,000,000 shares of common stock available
for grant under the 2001 Stock Option and Incentive Plan will
result in additional potential dilution of our outstanding
stock. Based solely on the closing price of our common stock as
reported on AMEX on November 16, 2007 of $61.75 per share,
the maximum aggregate market value of the additional
3,000,000 shares of common stock to be reserved for
issuance under the 2001 Stock Option and Incentive Plan would be
$185,250,000.
As of November 15, 2007, there were 59,223,073 shares
of our common stock outstanding. This share number does not
include (1) 2,654,590 shares that we issued on
November 16, 2007 as part of the purchase price for Alere
Medical, Inc., (2) 11,834,302 shares of common stock
that we expect to issue on November 20, 2007 upon the
closing of our previously announced public offering, or
(3) 1,800,000 shares of our common stock that the
underwriters of our public offering may purchase to cover
over-allotments.
Summary
of the 2001 Stock Option and Incentive Plan, as
Amended
Administration. The 2001 Stock Option and
Incentive Plan provides for administration by the Board or by a
committee of not fewer than two independent directors, referred
to as the administrator, provided that, for purposes
of awards to directors and Section 16 officers, the
administrator shall be deemed to include only directors who are
independent directors, as appointed by the Board from time to
time. The Board of Directors is currently serving as the
administrator of the 2001 Stock Option and Incentive Plan.
The administrator has full power to select, from among the
individuals eligible for awards, the individuals to whom awards
will be granted, to make any combination of awards to
participants, and to determine the specific terms and conditions
of each award, subject to the provisions of the 2001 Stock
Option and Incentive Plan. The administrator may permit common
stock, and other amounts payable pursuant to an award, to be
deferred. In such instances, the administrator may permit
interest, dividends or deemed dividends to be credited to the
amount of deferrals.
Eligibility and Limitations on Grants. All of
our officers, employees, directors, consultants and other key
persons are eligible to participate in the 2001 Stock Option and
Incentive Plan, subject to the discretion of
3
the administrator. In no event may any one participant receive
options to purchase more than 1,529,632 shares of common
stock, subject to adjustment for stock splits and similar
events, during any one calendar year. Approximately
4,500 people are currently eligible to participate in the
2001 Stock Option and Incentive Plan. The number of shares of
common stock that are available to be issued through grants or
awards made under the 2001 Stock Option and Incentive Plan or
through the exercise of options granted thereunder will be
increased from 8,074,081 shares to 11,074,081 shares,
but the 2001 Stock Option and Incentive Plan, as amended, will
provide that different types of awards will count differently
against the total number of shares available. Full value awards
settled in stock, other than an award that is a stock option or
other award that requires the grantee to purchase shares for
their fair market value at the time of grant, will be counted
against the overall share limitation as 3.0 shares. All
other awards will continue to be counted against the overall
share limitation as 1.0 share.
Stock Options. Options granted under the 2001
Stock Option and Incentive Plan may be either incentive stock
options, referred to as incentive options, within
the definition of Section 422 of the Internal Revenue Code,
or non-qualified stock options, referred to as
non-qualified options. Options granted under the
2001 Stock Option and Incentive Plan will be non-qualified
options if they fail to meet the Internal Revenue Code
definition of incentive options, are granted to a person not
eligible to receive incentive options under the Internal Revenue
Code, or otherwise so provide. Incentive options may be granted
only to officers or other employees of the Company or its
subsidiaries. Non-qualified options may be granted to persons
eligible to receive incentive options and to non-employee
directors and other key persons.
Other Option Terms. The administrator has
authority to determine the terms of options granted under the
2001 Stock Option and Incentive Plan. Options are granted with
an exercise price that is not less than the fair market value of
our common stock on the date of the option grant.
The life of each option will be fixed by the administrator and
may not exceed ten years from the date of grant. The
administrator will determine at what time or times each option
may be exercised and the period of time, if any, after
retirement, death, disability or termination of employment
during which options may be exercised. Options may be made
exercisable in installments, and the exercisability of options
may be accelerated by the administrator; provided that the
administrator may not accelerate the exercisability of options,
other than by reason of, or in connection with, death,
disability, retirement, employment termination (without cause)
or change of control, if the number of options so accelerated
when combined with the number of unrestricted stock awards
granted would exceed 10% of the maximum number of shares
issuable under the plan. In general, unless otherwise permitted
by the administrator, no option granted under the 2001 Stock
Option and Incentive Plan is transferable by the optionee other
than by will or by the laws of descent and distribution, and
options may be exercised during the optionees lifetime
only by the optionee, or by the optionees legal
representative or guardian in the case of the optionees
incapacity.
Options granted under the 2001 Stock Option and Incentive Plan
may be exercised by paying cash or by the transfer to us of
shares of common stock which are not then subject to
restrictions under the 2001 Stock Option and Incentive Plan or
any other stock plan that we maintain, which have been held by
the optionee for at least six months or were purchased on the
open market, and which have a fair market value equivalent to
the option exercise price of the shares being purchased. Such
options may also be exercised by compliance with certain
provisions pursuant to which a securities broker delivers the
purchase price for the shares to us.
At the discretion of the administrator, stock options granted
under the 2001 Stock Option and Incentive Plan may include a
reload feature pursuant to which an optionee
exercising an option by the delivery of shares of common stock
would automatically be granted an additional stock option to
purchase that number of shares of common stock equal to the
number delivered to exercise the original stock option. This
additional stock option would have an exercise price equal to
the fair market value of the common stock on the date the
additional stock option is granted. The purpose of this reload
feature is to enable participants to maintain an equity interest
in us without causing dilution.
To qualify as incentive options, options must meet additional
federal tax requirements, including a $100,000 limit on the
value of shares subject to incentive options which first become
exercisable in any one calendar year, and a shorter term and
higher minimum exercise price in the case of certain large
stockholders.
4
Restricted Stock Awards. The administrator may
grant or sell shares of common stock to any participant subject
to such conditions and restrictions as the administrator may
determine. The shares may be sold at par value or for a higher
purchase price determined by the administrator. These conditions
and restrictions may include the achievement of pre-established
performance goals
and/or
continued employment with us through a specified vesting period.
The vesting period shall be determined by the administrator but
shall be at least one year for attainment of pre-established
performance goals or at least three years for other conditions
and restrictions. If the applicable performance goals and other
restrictions are not attained, the participant will forfeit his
or her award of restricted stock.
Unrestricted Stock Awards. The administrator
may also grant shares of common stock which are free from any
restrictions under the 2001 Stock Option and Incentive Plan.
Unrestricted stock may be granted to any participant in
recognition of past services or other valid consideration, and
may be issued in lieu of cash compensation due to such
participant. The aggregate number of unrestricted stock awards
that may be granted under the plan, when combined with stock
underlying options that were accelerated other than by reason
of, or in connection with, death, disability, retirement,
employment termination (without cause) or change of control, may
not exceed 10% of the maximum number of shares issuable under
the plan.
Deferred Stock Awards. The administrator may
also award phantom stock units as deferred stock awards to
participants. The deferred stock awards are ultimately payable
in the form of shares of common stock and may be subject to such
conditions and restrictions as the administrator may determine.
These conditions and restrictions may include the achievement of
certain performance goals
and/or
continued employment with us through a specified vesting period.
The vesting period shall be determined by the administrator but
shall be at least one year for attainment of pre-established
performance goals or at least three years for other conditions
and restrictions. During the deferral period, subject to terms
and conditions imposed by the administrator, the deferred stock
awards may be credited with dividend equivalent rights. Subject
to the consent of the administrator, a participant may make an
advance election to receive a portion of his compensation or
restricted stock award otherwise due in the form of a deferred
stock award.
Performance Share Awards. The administrator
may grant performance share awards to any participant which
entitle the recipient to receive shares of common stock upon the
achievement of individual or company performance goals and such
other conditions as the administrator shall determine. The
periods during which performance is to be measured shall not be,
in the aggregate, less than one year.
Dividend Equivalent Rights. The administrator
may grant dividend equivalent rights, which entitle the
recipient to receive credits for dividends that would be paid if
the grantee held specified shares of common stock. Dividend
equivalent rights may be granted as a component of another award
or as a freestanding award.
Change of Control Provisions. The 2001 Stock
Option and Incentive Plan provides that in the event of a
change of control as defined in the 2001 Stock
Option and Incentive Plan, all stock options will automatically
become fully exercisable and the restrictions and conditions on
all other awards will automatically be deemed waived, unless
otherwise provided in the applicable award agreement.
Adjustments for Stock Dividends, Mergers,
etc. The 2001 Stock Option and Incentive Plan
authorizes the administrator to make appropriate adjustments to
the number of shares of common stock that are subject to the
2001 Stock Option and Incentive Plan and to any outstanding
awards to reflect stock dividends, stock splits and similar
events. In the event of certain transactions, such as a merger,
consolidation, dissolution or liquidation of our company, the
2001 Stock Option and Incentive Plan and all awards will
terminate unless the parties to the transaction, in their
discretion, provide for appropriate substitutions or adjustments
of outstanding stock options or awards. Before any outstanding
stock options and awards terminate, the option holder will have
an opportunity to exercise all outstanding options, and holders
of other awards will receive a cash or in kind payment of such
appropriate consideration as determined by the administrator in
its sole discretion after taking into account the consideration
payable per share of common stock pursuant to the business
combination. The administrator may adjust the number of shares
subject to outstanding awards and the exercise price and the
terms of outstanding awards to take into consideration material
changes in accounting practices or principles, extraordinary
dividends, acquisitions or dispositions of stock or property or
any other event if it is determined by the administrator that
such adjustment is appropriate to avoid distortion in the
operation of the
5
2001 Stock Option and Incentive Plan, provided that no such
adjustment shall be made in the case of an incentive stock
option, without the consent of the grantee, if it would
constitute a modification, extension or renewal of the option
within the meaning of Section 424(h) of the Code.
Amendments and Termination. Subject to
requirements of law or the rules of any stock exchange, the
Board may at any time amend or discontinue the 2001 Stock Option
and Incentive Plan and the administrator may at any time amend
or cancel any outstanding award for the purpose of satisfying
changes in law or for any other lawful purpose, but no such
action shall adversely affect the rights under any outstanding
awards without the holders consent. To the extent required
by the Internal Revenue Code to ensure that options granted
under the 2001 Stock Option and Incentive Plan qualify as
incentive options or that compensation earned under the options
granted under the 2001 Stock Option and Incentive Plan qualifies
as performance-based compensation under the Internal Revenue
Code, plan amendments shall be subject to approval by our
stockholders.
No grants have been made with respect to the additional shares
of common stock to be reserved for issuance under the 2001 Stock
Option and Incentive Plan. The number of shares of common stock
that may be granted to executive officers and all employees,
including non-executive officers and directors who are
employees, and to independent directors is indeterminable at
this time, as such grants are subject to the discretion of the
Compensation Committee and the Board. The Compensation Committee
recommends, and the Board approves, stock option grants to our
officers and employees on a regular basis.
Material
Federal Income Tax Consequences
The following discussion describes the material federal income
tax consequences of transactions under the 2001 Stock Option and
Incentive Plan. It does not describe all federal tax
consequences under the 2001 Stock Option and Incentive Plan, nor
does it describe state or local tax consequences.
Incentive Options. No taxable income is
generally realized by the optionee upon the grant or exercise of
an incentive option. If shares of common stock issued to an
optionee pursuant to the exercise of an incentive option are
sold or transferred after two years from the date of grant and
after one year from the date of exercise, then upon sale of such
shares, any amount realized in excess of the option price will
be taxed to the optionee as a long-term capital gain, and any
loss sustained will be a long-term capital loss, and we will not
have a deduction for federal corporate income tax purposes. The
exercise of an incentive option will give rise to an item of tax
preference that may result in alternative minimum tax liability
for the optionee.
If shares of common stock acquired upon the exercise of an
incentive option are disposed of prior to the expiration of the
two-year and one-year holding periods described above, a
disqualifying disposition, generally the optionee
will realize ordinary income in the year of disposition in an
amount equal to the excess, if any, of the fair market value of
the shares of common stock at exercise (or, if less, the amount
realized on a sale of such shares of common stock) over the
option price thereof, and we will be entitled to deduct such
amount. Special rules will apply where all or a portion of the
exercise price of the incentive option is paid by tendering
shares of common stock.
If an incentive option is exercised at a time when it no longer
qualifies for the tax treatment described above, the option is
treated as a non-qualified option. Generally, an incentive
option will not be eligible for the tax treatment described
above if it is exercised more than three months following
termination of employment, or one year in the case of
termination of employment by reason of disability. In the case
of termination of employment by reason of death, the three-month
rule does not apply.
Non-Qualified Options. With respect to
non-qualified options under the 2001 Stock Option and Incentive
Plan, no income is realized by the optionee at the time the
option is granted. Generally,
|
|
|
|
|
at exercise, ordinary income is realized by the optionee in an
amount equal to the difference between the option price and the
fair market value of the shares of common stock on the date of
exercise, and we receive a tax deduction for the same
amount, and
|
6
|
|
|
|
|
at disposition, appreciation or depreciation after the date of
exercise is treated as either short-term or long-term capital
gain or loss depending on how long the shares of common stock
have been held.
|
Special rules will apply where all or a portion of the exercise
price of the non-qualified option is paid by tendering shares of
common stock.
Parachute Payments. The vesting or
exercisability of any portion of any option or other award that
is accelerated due to the occurrence of a change of control may
cause a portion of the payments with respect to such accelerated
awards to be treated as parachute payments as
defined in the Internal Revenue Code. Any such parachute
payments may be non-deductible to us, in whole or in part, and
may subject the recipient to a non-deductible 20% federal excise
tax on all or a portion of such payment in addition to other
taxes ordinarily payable.
Limitation on Our Deductions. As a result of
Section 162(m) of the Internal Revenue Code, our deduction
for certain awards under the 2001 Stock Option and Incentive
Plan may be limited to the extent that a covered employee
receives compensation in excess of $1,000,000 in such taxable
year, other than performance-based compensation that otherwise
meets the requirements of Section 162(m) of the Internal
Revenue Code.
The approval of the proposal to amend the 2001 Stock Option and
Incentive Plan to increase the number of shares of common stock
available for issuance thereunder requires the affirmative vote
of a majority of the votes properly cast for and against the
proposal. In accordance with Delaware law and our bylaws,
abstentions and broker non-votes will not be counted as votes
cast on this matter and, accordingly, will have no effect.
The Board unanimously recommends a vote FOR the approval
of the amendment to the 2001 Stock Option and Incentive Plan
increasing the number of shares of common stock available
thereunder.
7
The following table furnishes information as to shares of our
common stock beneficially owned by:
|
|
|
|
|
each person or entity known by us to beneficially own more than
five percent of our common stock;
|
|
|
|
each of our directors;
|
|
|
|
each of our named executive officers (as defined in
Compensation of Executive Officers on
page 14); and
|
|
|
|
all of our directors and executive officers as a group.
|
Unless otherwise stated, beneficial ownership is calculated as
of October 31, 2007. For the purpose of this table, a
person, group or entity is deemed to have beneficial
ownership of any shares that such person, group or entity
has the right to acquire within 60 days after such date
through the exercise of options or warrants.
Security
Ownership of Certain Beneficial Owners and Management
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
|
Amount and
|
|
|
|
|
|
|
Nature of
|
|
|
Percent
|
|
|
|
Beneficial
|
|
|
of
|
|
Name and Address of Beneficial Owner (1)
|
|
Ownership(2)
|
|
|
Class(3)
|
|
FMR Corp.
|
|
|
|
|
|
|
|
|
Edward C. Johnson 3d(4)
|
|
|
5,819,013
|
|
|
|
10.49
|
%
|
Fidelity Management & Research Company(4)
|
|
|
5,574,319
|
|
|
|
10.05
|
%
|
Zwanziger Family Ventures, LLC(5)
|
|
|
1,806,696
|
|
|
|
3.25
|
%
|
Ron Zwanziger(6)
|
|
|
3,361,513
|
|
|
|
6.04
|
%
|
David Scott, Ph.D.(7)
|
|
|
745,781
|
|
|
|
1.34
|
%
|
Jerry McAleer, Ph.D.(8)
|
|
|
672,139
|
|
|
|
1.20
|
%
|
Christopher J. Lindop(9)
|
|
|
15,191
|
|
|
|
*
|
|
David Teitel(10)
|
|
|
24,654
|
|
|
|
*
|
|
David Toohey(11)
|
|
|
113,872
|
|
|
|
*
|
|
John Bridgen, Ph.D.(12)
|
|
|
96,797
|
|
|
|
*
|
|
Carol R. Goldberg(13)
|
|
|
109,364
|
|
|
|
*
|
|
Robert P. Khederian(14)
|
|
|
161,667
|
|
|
|
*
|
|
John F. Levy(15)
|
|
|
155,360
|
|
|
|
*
|
|
John A. Quelch(16)
|
|
|
41,667
|
|
|
|
*
|
|
Peter Townsend
|
|
|
0
|
|
|
|
*
|
|
All current executive officers and directors (20 persons)(17)
|
|
|
6,057,576
|
|
|
|
10.61
|
%
|
|
|
|
* |
|
Represents less than 1% |
|
(1) |
|
The address of each director or executive officer (and any
related persons or entities) is c/o the Company at its
principal office. |
|
(2) |
|
Unless otherwise indicated, the stockholders identified in this
table have sole voting and investment power with respect to the
shares beneficially owned by them. |
|
(3) |
|
The number of shares outstanding used in calculating the
percentage for each person, group or entity listed includes the
number of shares underlying options and warrants held by such
person or group that were exercisable within 60 days from
October 31, 2007, but excludes shares of stock underlying
options and warrants held by any other person. |
8
|
|
|
(4) |
|
This information is based on information contained in a
Schedule 13G/A filed with the SEC on February 14, 2007
by FMR Corp., Edward C. Johnson 3d and Fidelity
Management & Research Company. The address provided
therein for each of these persons is 82 Devonshire Street,
Boston, MA 02109. None of these persons have voting power over
any of the shares, except that FMR Corp. has sole voting power
with respect to 251,294 shares. |
|
(5) |
|
Consists of 1,652,476 shares of common stock and
36,794 shares of common stock underlying warrants
exercisable within 60 days from October 31, 2007. Ron
Zwanziger, our Chairman, Chief Executive Officer and President,
and Janet M. Zwanziger, his spouse, are the managers of
Zwanziger Family Ventures, LLC and each have shared voting and
investment power over these securities. |
|
(6) |
|
Consists of 3,217,078 shares of common stock and
144,435 shares of common stock underlying warrants and
options exercisable within 60 days from October 31,
2007. Of the shares attributed to Mr. Zwanziger,
664,142 shares of common stock are owned by
Mr. Zwanziger as Trustee of the Zwanziger 2004 Annuity
Trust, and 1,769,902 shares of common stock and
36,794 shares of common stock issuable upon the exercise of
warrants are owned by Zwanziger Family Ventures, LLC, a limited
liability company managed by Mr. Zwanziger and his spouse.
Of the other shares attributed to him, Mr. Zwanziger
disclaims beneficial ownership of (i) 2,600 shares
owned by his wife, Janet M. Zwanziger, and
(ii) 9,450 shares owned by the Zwanziger Goldstein
Foundation, a charitable foundation for which Mr. Zwanziger
and his spouse, along with three others, serve as directors. |
|
(7) |
|
Consists of 450,554 shares of common stock and
295,227 shares of common stock underlying options
exercisable within 60 days from October 31, 2007.
Includes 44,788 shares of common stock to be sold in a
public offering expected to close on November 20, 2007. |
|
(8) |
|
Consists of 276,559 shares of common stock and
395,580 shares of common stock underlying options
exercisable within 60 days from October 31, 2007.
Includes 75,000 shares of common stock to be sold in a
public offering expected to close on November 20, 2007. |
|
(9) |
|
Consists of 15,191 shares of common stock owned by
Mr. Lindop as of February 1, 2007. Mr. Lindop
resigned as Chief Financial Officer on December 8, 2006. |
|
(10) |
|
Consists of 904 shares of common stock and
23,750 shares of common stock underlying options
exercisable within 60 days from October 31, 2007. |
|
(11) |
|
Consists of 6,491 shares of common stock and
107,381 shares of common stock underlying options
exercisable within 60 days from October 31, 2007.
Includes 13,480 shares of common stock to be sold in a
public offering expected to close on November 20, 2007. |
|
(12) |
|
Consists of 2,633 shares of common stock and
94,164 shares of common stock underlying options
exercisable within 60 days from October 31, 2007.
Includes 13,430 shares of common stock to be sold in a
public offering expected to close on November 20, 2007. |
|
(13) |
|
Consists of 67,697 shares of common stock and
41,667 shares of common stock underlying options
exercisable within 60 days from October 31, 2007. |
|
(14) |
|
Consists of 120,000 shares of common stock and
41,667 shares of common stock underlying options
exercisable within 60 days from October 31, 2007. |
|
(15) |
|
Consists of 104,118 shares of common stock and
51,242 shares of common stock underlying warrants and
options exercisable within 60 days from October 31,
2007. Of the shares attributed to him, Mr. Levy disclaims
beneficial ownership of 741 shares of common stock and
warrants to purchase 266 shares of common stock owned by a
charitable remainder unitrust. |
|
(16) |
|
Consists of 41,667 shares of common stock underlying
options exercisable within 60 days from October 31,
2007. |
|
(17) |
|
Consists of 4,421,472 shares of common stock and
1,636,104 shares of common stock underlying warrants and
options exercisable within 60 days from October 31,
2007. Includes 165,698 shares of common stock to be sold in
a public offering expected to close on November 20, 2007.
See also footnotes (6)-(16) |
9
COMPENSATION
DISCUSSION AND ANALYSIS
This Compensation Discussion and Analysis discusses the
compensation paid to our three key executives, as defined below,
our chief financial officer, or our CFO, our former CFO, and our
other two most highly-compensated executive officers. These
officers are collectively referred to as the named executive
officers. Our key executives are Ron Zwanziger, CEO; David
Scott, Ph. D., Chief Scientific Officer and Jerry McAleer,
Ph. D., Vice President, Research and Development and Vice
President, Cardiology.
Philosophy
and Objectives
The objective of our executive compensation program is to
attract, retain and motivate the talented and dedicated
executives who are critical to our goals of continued growth,
innovation, increasing profitability and ultimately maximizing
shareholder value. Specifically, we seek to attract and reward
executives who display certain fundamental leadership
characteristics for hiring and promotion that we have identified
as consistent with our company goals and culture. We provide
these executives with what we believe to be a competitive total
compensation package consisting primarily of base salary,
long-term equity incentive compensation and a broad-based
benefits program. Our compensation program is designed to reward
each executives individual performance by considering
generally their past and potential contribution to our
achievement of key strategic goals such as revenue generation,
margin improvement and the establishment and maintenance of key
strategic relationships. Our executive compensation program aims
to provide a compensation package which is competitive in our
market sector and, more important, relevant to the individual
executive.
Our policy for allocating between long-term and currently paid
compensation is to ensure adequate base compensation to attract
and retain personnel, while providing incentives to maximize
long term value for our company and our stockholders.
Accordingly, (i) we provide cash compensation in the form
of base salary to meet competitive salary norms and reward good
performance on an annual basis and (ii) we provide non-cash
compensation, primarily in the form of stock-based awards, to
reward superior performance against long-term strategic goals.
Executive
Compensation Process
The compensation of our named executive officers, as well as our
other executive officers, is reviewed by our Compensation
Committee at least annually for consistency with the objectives
described above. Our management, including our CEO, participates
in this review by making its own recommendations as to the
compensation of our executive officers to the Compensation
Committee. The Compensation Committee considers the
recommendations of management in assessing executive
compensation but also relies on other data and resources and may
utilize the services of a compensation consultant in reviewing
and determining executive compensation.
In reviewing executive compensation, the Compensation Committee
and management also consider the practices of comparable
companies of similar size, geographic location and market focus.
Management and the Compensation Committee utilize the Radford
Global Life Sciences Survey, a subscription service that
provides comprehensive baseline compensation data on positions
at the executive, management and professional levels, including
salary, total cash compensation, options and equity
compensation, and occasionally collect and analyze publicly
available compensation data and other subscription compensation
survey data. While benchmarking may not always be appropriate as
a standalone tool for setting compensation due to the aspects of
our business and objectives that may be unique to us, we
generally believe that gathering this compensation information
is an important part of our compensation-related decision making
process. The Compensation Committee did not utilize the services
of a compensation consultant during 2006. For 2007, however, the
Compensation Committee has engaged a compensation consultant,
Pearl Meyer & Company, to assist the committee in
assessing executive compensation. Specifically, the Committee
has engaged Pearl Meyer to review and provide guidance with
respect to the CEOs recommendations as to the total cash
compensation paid to our executive officers.
10
In determining each component of an executives
compensation, numerous factors are considered, including:
|
|
|
|
|
The individuals particular background and circumstances,
including prior relevant work experience;
|
|
|
|
The demand for individuals with the executives specific
expertise and experience;
|
|
|
|
The individuals role with us and the compensation paid to
similar persons determined through benchmark studies;
|
|
|
|
The individuals performance and contribution to our
achievement of company goals and objectives; and
|
|
|
|
Comparison to other executives within our company.
|
In considering the compensation paid to our three key
executives, as identified above, our Compensation Committee also
considered in particular the compensation packages awarded to
the key executives during 2001 in anticipation of our split-off
from Inverness Medical Technology, or the 2001 compensation
packages. The 2001 compensation packages, which were approved by
the stockholders of Inverness Medical Technology (who became our
stockholders at the time of the split-off), were comprehensive,
multi-year packages providing for compensation through 2006.
They were designed to (i) ensure that the key executive
remained with us after the split-off, (ii) properly
compensate the key executive for the risks they were assuming in
committing to guide a newly-formed entity with no independent
track record and no existing trading market for its stock and
(iii) reward the key executive in the event we met
aggressive market-based performance goals.
The 2001 compensation packages consisted of both stock-based
awards, fixed cash bonuses and a performance-based bonus plan.
With respect to the stock-based awards, Mr. Zwanziger was
given the opportunity to purchase, and did purchase,
1,168,191 shares of restricted stock vesting over four
years (all of which are now fully vested). Dr. Scott and
Dr. McAleer were granted options to purchase 399,381 and
379,413 shares, respectively, of restricted stock vesting
over four years. Dr. Scotts option, and a portion of
Dr. McAleers option, were exercised using promissory
notes, as discussed under Certain Relationships and
Related Transactions Indebtedness of Certain
Executive Officers and Directors on page 26 of this
proxy statement. With respect to the fixed cash bonuses, for
each of fiscal years 2001 through 2006 each key executive
received the following year-end bonuses payable during the month
of January of the following year:
|
|
|
|
|
|
|
|
|
|
|
Annual Bonus
|
|
|
Annual Bonus
|
|
Key Executive
|
|
2001
|
|
|
2002-2006
|
|
|
Ron Zwanziger
|
|
$
|
225,000
|
|
|
$
|
550,000
|
|
David Scott
|
|
$
|
55,000
|
|
|
$
|
125,000
|
|
Jerry McAleer
|
|
$
|
50,000
|
|
|
$
|
120,000
|
|
The 2001 compensation packages also included an additional bonus
plan which provided that each of the key executives would
automatically be granted ten-year, non-qualified stock options
if our common stock achieved specified stock price targets by
specified target dates. These awards have lapsed.
Executive compensation consists of the following elements:
Base Salary. Generally, annual base salary for
a particular individual is established based on the factors
discussed above and is intended to be near the average of the
range of salaries for executives in similar positions with
similar responsibilities at comparable companies, although other
elements of compensation, including past and present grants of
stock-based awards, may also be considered. The Compensation
Committee believes that a competitive base salary is necessary
to attract and retain a management team with the request skills
to lead our company. The base salary of the key executives had
not been adjusted since 2001 because our Compensation Committee
determined that their salaries remained fair and equitable when
considering all elements of the 2001 compensation packages.
During 2006, our Compensation Committee considered the fact that
the performance-based awards under the 2001 compensation plan
lapsed at the end of 2005 and the annual cash bonuses described
above would cease after 2006. As a result, the Compensation
11
Committee recommended that the salaries of the
Mr. Zwanziger, Dr. Scott and Dr. McAleer be
increased to $750,000, $600,000, and $500,000, respectively. Our
Board of Directors (in the absence of the key executives who are
also directors) approved these new salaries effective
July 1, 2006. Additionally, David Teitels salary was
increased to $215,000 in December 2006, upon his promotion to
Chief Financial Officer.
Bonuses. Our key executives received the cash
bonuses described above as part of the shareholder-approved 2001
compensation packages. During 2006, our Compensation Committee
increased the annual salary of the key executives but decided
not to renew or replace the annual cash bonuses which were a
part of the 2001 compensation packages. Our other named
executive officers did not receive bonuses during 2006, although
David Teitel did receive a $5,000 bonus on January 13, 2006
prior to becoming an executive officer of the Company. While our
Compensation Committee reserves the right to grant cash or
non-cash bonuses as a performance incentive or reward, it
currently has no plans to grant bonuses to the named executive
officers during 2007. Cash bonuses are generally not a regular
or important element of our executive compensation strategy and
we focus instead on stock-based awards designed to reward
long-term performance.
Stock Option and Stock-Based Awards. We
believe long-term performance is best stimulated through an
ownership culture that encourages such performance through the
use of stock-based awards. The Inverness Medical Innovations,
Inc. 2001 Stock Option and Incentive Plan, or the 2001 Option
Plan, was established to provide certain of our employees,
including our executive officers, with incentives to help align
those employees interests with the interests of
stockholders and with our long-term success. The Compensation
Committee believes that the use of stock options and other
stock-based awards offers the best approach to achieving our
long-term compensation goals.
While the 2001 Option Plan allows our Compensation Committee to
grant a number of different types of stock-based awards, other
than one restricted stock grant made to Mr. Zwanziger in
2001 as part of the 2001 compensation package, we have relied
exclusively on stock options to provide equity incentive
compensation. Stock options granted to our executive officers
have an exercise price equal to the fair market value of our
common stock on the grant date, typically vest 25% per annum
based upon continued employment over a four-year period, and
generally expire ten years after the date of grant. Stock option
grants to our executive officers are made in connection with the
commencement of employment, in conjunction with an annual review
of total compensation and, occasionally, following a significant
change in job responsibilities or to meet other special
retention or performance objectives. Proposals to grant stock
options to our executive officers are made by our CEO to the
Compensation Committee. With respect to proposals for grants
made to our executive officers, the Committee reviews
competitive compensation survey data, as discussed above,
individual performance, the executives existing
compensation and other retention considerations. The
Compensation Committee considers the Black-Scholes valuation of
each proposed stock option grant in determining the number of
options subject to each grant.
Generally, stock option grants to executive officers have been
made in conjunction with meetings of the Board of Directors.
During 2007, we adopted a stock option granting policy that
includes the following elements:
|
|
|
|
|
Options to purchase shares of our common stock shall be granted
effective as of the last calendar day of the following months:
February, April, June, August, October and December (each such
date a Grant Date);
|
|
|
|
For each employee (or prospective employee) that is not (or,
upon hire, will not be) subject to Section 16 of the
Exchange Act, the CEO shall have the authority to grant, in his
sole discretion, an option or options to purchase up to an
aggregate of 5,000 shares of common stock (on an annual
basis); provided, however, that total number of shares of common
stock underlying such options grants shall not exceed 150,000
per calendar year;
|
|
|
|
The Compensation Committee must approve all other stock option
grants. Grants by the Compensation Committee must be approved
only at a meeting of the Compensation Committee and not by
written consent;
|
12
|
|
|
|
|
Grants of options approved for existing employees, shall be
effective as of, and the grant date thereof shall for all
purposes be deemed to be, the Grant Date following the date of
approval (except that any grants subject to stockholder approval
shall be effective as of the date of stockholder
approval); and
|
|
|
|
Options approved for new hires, including those hired through
acquisitions, shall be effective as of, and the grant date
thereof shall for all purposes be deemed to be, the Grant Date
following the later of (i) the date of such approval or
(ii) the date on which the new hires employment
commences.
|
We have not adopted stock ownership guidelines.
During 2006, David Teitel was granted options to purchase
25,000 shares of common stock. The rationale for these
grants is discussed on page 20 of this proxy statement. In
addition, during 2007 our Compensation Committee considered the
fact that the performance-based awards under the 2001
compensation packages lapsed at the end of 2005 and approved
grants of stock options to purchase 300,000, 150,000 and
125,000 shares of common stock to Ron Zwanziger, David
Scott and Jerry McAleer, respectively. These grants were
approved by our stockholders at our 2007 annual meeting.
Other Compensation. Our named executive
officers do not have employment agreements. The named executive
officers are not eligible to participate in, and do not have any
accrued benefits under, any Company-sponsored defined benefit
pension plan. They are eligible to, and in some case do,
participate in defined contributions plans, such as a 401(k)
plan, on the same terms as other employees. The terms of these
defined contribution plans vary depending on the jurisdiction of
employment of the executive. In addition, consistent with our
compensation philosophy, we intend to continue to maintain our
current benefits and perquisites for our executive officers;
however, the Compensation Committee in its discretion may
revise, amend or add to the officers executive benefits
and perquisites if it deems it advisable. We believe these
benefits and perquisites are currently lower than median
competitive levels for comparable companies. Finally, all of our
executives are eligible to participate in our other employee
benefit plans, including, medical, dental, life and disability
insurance.
Section 162(m) of the Internal Revenue Code of 1986, as
amended, limits the deductibility on our tax return of
compensation of over $1,000,000 to any of the named executive
officers unless, in general, the compensation is paid pursuant
to a plan which is performance-related, non-discretionary and
has been approved by our stockholders. We periodically review
the potential consequences of Section 162(m) and may
structure the performance-based portion of our executive
compensation to comply with the exemptions available under
Section 162(m). However, we reserve the right to use our
judgment to authorize compensation payments that do not comply
with these exemptions when we believe that such payments are
appropriate and in the best interest of the stockholders, after
taking into consideration changing business conditions or the
officers performance.
13
COMPENSATION
OF EXECUTIVE OFFICERS AND DIRECTORS
Set forth below is information regarding the compensation of our
Chief Executive Officer, our Chief Financial Officer, our former
Chief Financial Officer, our three other most highly compensated
executive officers, and one of our key executive officers for
the fiscal year 2006. Such officers are collectively referred to
as the named executive officers.
Summary Compensation Table. The
following table sets forth information regarding the named
executive officers compensation for fiscal year 2006.
Summary
Compensation Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option
|
|
|
All Other
|
|
|
|
|
|
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Awards
|
|
|
Compensation
|
|
|
Total
|
|
Name and Principal Position
|
|
Year
|
|
|
($)
|
|
|
($)(1)
|
|
|
($)(2)
|
|
|
($)(3)
|
|
|
($)
|
|
|
Ron Zwanziger
|
|
|
2006
|
|
|
$
|
550,000
|
|
|
$
|
550,000
|
|
|
|
|
|
|
$
|
999
|
|
|
$
|
1,100,999
|
|
Chairman, Chief Executive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Officer and President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Teitel(4)
|
|
|
2006
|
|
|
$
|
192,885
|
|
|
$
|
5,000
|
|
|
$
|
63,322
|
|
|
$
|
6,327
|
|
|
$
|
267,534
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Bridgen, Ph.D.
|
|
|
2006
|
|
|
$
|
363,600
|
|
|
|
|
|
|
$
|
191,572
|
|
|
$
|
7,590
|
|
|
$
|
562,762
|
|
Vice President, Strategic Business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Toohey(5)
|
|
|
2006
|
|
|
$
|
426,924
|
|
|
|
|
|
|
$
|
68,310
|
|
|
$
|
63,824
|
|
|
$
|
559,058
|
|
President, Professional Diagnostics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Scott, Ph.D.(6)
|
|
|
2006
|
|
|
$
|
431,177
|
|
|
$
|
125,000
|
|
|
|
|
|
|
|
|
|
|
$
|
556,177
|
|
Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerry McAleer, Ph.D.(5)
|
|
|
2006
|
|
|
$
|
364,111
|
|
|
$
|
120,000
|
|
|
|
|
|
|
|
|
|
|
$
|
484,111
|
|
Vice President, Research & Development and Vice
President, Cardiology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christopher J. Lindop(7)
|
|
|
2006
|
|
|
$
|
375,000
|
|
|
|
|
|
|
$
|
221,782
|
|
|
$
|
7,590
|
|
|
$
|
604,372
|
|
Former Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Except with respect to David Teitel, the amounts in this column
reflect bonuses paid as part of the shareholder-approved 2001
compensation packages described in the Compensation
Discussion and Analysis section beginning on page 10
of this proxy statement. The 2001 compensation packages, which
were awarded in anticipation of our spin off from Inverness
Medical Technology, provided in part for fixed cash bonuses to
be paid through 2006, the final year of the 2001 compensation
packages. |
|
(2) |
|
The amounts in this column reflect the dollar amount recognized
for financial statement reporting purposes for the fiscal year
ended December 31, 2006, in accordance with FAS 123(R)
and thus may include amounts from awards granted in and prior to
2006. Assumptions used in the calculation of these amounts are
included in Note 15 in the notes to our audited
consolidated financial statements for the fiscal year ended
December 31, 2006 included in our Annual Report on
Form 10-K/A
filed with the Securities and Exchange Commission on
March 26, 2007. |
|
(3) |
|
The amounts in this column include (a) matching
contributions made by our company to our defined contribution
plans in the amount of $5,654, $6,600, $63,824 and $6,600 on
behalf of Mr. Teitel, Dr. Bridgen, Mr. Toohey and
Mr. Lindop, respectively, and (b) life insurance
premiums paid by our company in the amount of $990, $673, $990
and $990 on behalf of Mr. Zwanziger, Mr. Teitel,
Dr. Bridgen and Mr. Lindop, respectively. |
|
(4) |
|
Mr. Teitel was appointed as Chief Financial Officer on
December 8, 2006. |
|
(5) |
|
Salary and other compensation paid in Euros. Euros were
converted to U.S. dollars using the average exchange rate for
the year reported. |
14
|
|
|
(6) |
|
Salary and other compensation paid in British pounds. British
pounds were converted to U.S. dollars using the average exchange
rate for the year reported. |
|
(7) |
|
Mr. Lindop resigned as Chief Financial Officer on
December 8, 2006. |
Grants of Plan-Based Awards. The
following table sets forth certain information with respect to
options granted to the named executive officers in fiscal year
2006.
Grants
of Plan-Based Awards 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards:
|
|
|
Exercise or
|
|
|
Grant Date
|
|
|
|
|
|
|
Number of
|
|
|
Base Price
|
|
|
Fair Value
|
|
|
|
|
|
|
Securities
|
|
|
of Option
|
|
|
of Stock
|
|
|
|
Grant
|
|
|
Underlying
|
|
|
Awards
|
|
|
and Option
|
|
Name
|
|
Date
|
|
|
Options (#)(1)
|
|
|
($/Sh)(2)
|
|
|
Awards(3)
|
|
|
Ron Zwanziger
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Teitel
|
|
|
10/04/06
|
|
|
|
5,000
|
|
|
$
|
34.40
|
|
|
$
|
82,869
|
|
|
|
|
12/15/06
|
|
|
|
20,000
|
|
|
$
|
38.10
|
|
|
$
|
367,130
|
|
John Bridgen, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Scott, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Toohey
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerry McAleer, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christopher J. Lindop
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
All stock option awards were made under our 2001 Stock Option
and Incentive Plan. |
|
(2) |
|
The exercise price of the stock option awards is equal to the
closing price of the common stock on the grant date as reported
by the American Stock Exchange. |
|
(3) |
|
The amounts in this column reflect the grant date fair value of
each option award computed in accordance with FAS 123(R).
Assumptions used in the calculation of these amounts are
included in Note 15 of the notes to our audited
consolidated financial statements for the fiscal year ended
December 31, 2006 included in our Annual Report on Form
10-K/A filed
with the Securities and Exchange Commission on March 26,
2007. |
Mr. Teitel was granted options to purchase
5,000 shares at a Board of Directors meeting held on
October 4, 2006 in his role as Vice President, Finance
prior to his promotion to Chief Financial Officer. In connection
with his appointment as CFO on December 8, 2006, the Board
of Directors granted Mr. Teitel an option to purchase
20,000 shares. The terms of these options provide for
vesting in four equal annual installments, commencing on the
first anniversary of the date of grant. The options will expire
on the tenth anniversary of the grant date.
15
Outstanding Equity Awards at Fiscal
Year-End. The following table sets forth
certain information with respect to unexercised options held by
the named executive officers at the end of fiscal year 2006.
Outstanding
Equity Awards at Fiscal Year-End 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
|
|
|
|
Unexercised
|
|
|
Option
|
|
|
|
|
|
|
Number of Securities
|
|
|
Options
|
|
|
Exercise
|
|
|
Option
|
|
|
|
Underlying Unexercised
|
|
|
(#)(1)
|
|
|
Price
|
|
|
Expiration
|
|
Name
|
|
Options (#) Exercisable
|
|
|
Unexercisable
|
|
|
($)
|
|
|
Date(2)
|
|
|
Ron Zwanziger
|
|
|
6,702
|
|
|
|
|
|
|
$
|
14.92
|
|
|
|
2/12/2011
|
|
|
|
|
23,298
|
|
|
|
|
|
|
$
|
14.92
|
|
|
|
2/12/2011
|
|
|
|
|
65,000
|
|
|
|
|
|
|
$
|
17.15
|
|
|
|
12/20/2011
|
|
|
|
|
5,065
|
|
|
|
|
|
|
$
|
15.55
|
|
|
|
8/23/2012
|
|
|
|
|
7,576
|
|
|
|
|
|
|
$
|
21.78
|
|
|
|
12/31/2013
|
|
David Teitel
|
|
|
7,500
|
|
|
|
2,500
|
|
|
$
|
21.38
|
|
|
|
12/11/2013
|
|
|
|
|
5,000
|
|
|
|
5,000
|
|
|
$
|
24.25
|
|
|
|
12/17/2014
|
|
|
|
|
|
|
|
|
5,000
|
|
|
$
|
34.40
|
|
|
|
10/4/2016
|
|
|
|
|
|
|
|
|
20,000
|
|
|
$
|
38.10
|
|
|
|
12/15/2016
|
|
John Bridgen, Ph.D.
|
|
|
50,000
|
|
|
|
|
|
|
$
|
11.75
|
|
|
|
9/20/2012
|
|
|
|
|
6,664
|
|
|
|
|
|
|
$
|
21.78
|
|
|
|
12/31/2013
|
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
$
|
24.25
|
|
|
|
12/17/2014
|
|
David Scott, Ph.D.
|
|
|
14,000
|
|
|
|
|
|
|
$
|
1.71
|
|
|
|
10/13/2008
|
|
|
|
|
50,000
|
|
|
|
|
|
|
$
|
2.44
|
|
|
|
8/16/2009
|
|
|
|
|
24,000
|
|
|
|
|
|
|
$
|
14.92
|
|
|
|
2/12/2011
|
|
|
|
|
199,691
|
|
|
|
|
|
|
$
|
15.47
|
|
|
|
11/30/2011
|
|
|
|
|
2,284
|
|
|
|
|
|
|
$
|
15.60
|
|
|
|
9/3/2012
|
|
|
|
|
5,252
|
|
|
|
|
|
|
$
|
21.78
|
|
|
|
12/31/2013
|
|
David Toohey
|
|
|
10,000
|
|
|
|
|
|
|
$
|
11.80
|
|
|
|
3/15/2011
|
|
|
|
|
75,000
|
|
|
|
|
|
|
$
|
15.47
|
|
|
|
11/30/2011
|
|
|
|
|
3,631
|
|
|
|
|
|
|
$
|
15.55
|
|
|
|
8/23/2012
|
|
|
|
|
12,500
|
|
|
|
12,500
|
|
|
$
|
24.25
|
|
|
|
12/17/2014
|
|
Jerry McAleer, Ph.D.
|
|
|
14,000
|
|
|
|
|
|
|
$
|
1.71
|
|
|
|
10/13/2008
|
|
|
|
|
40,000
|
|
|
|
|
|
|
$
|
2.44
|
|
|
|
8/16/2009
|
|
|
|
|
16,000
|
|
|
|
|
|
|
$
|
14.92
|
|
|
|
2/12/2011
|
|
|
|
|
189,706
|
|
|
|
|
|
|
$
|
15.47
|
|
|
|
11/30/2011
|
|
|
|
|
129,413
|
|
|
|
|
|
|
$
|
16.76
|
|
|
|
12/2/2011
|
|
|
|
|
1,805
|
|
|
|
|
|
|
$
|
15.60
|
|
|
|
9/3/2012
|
|
|
|
|
4,656
|
|
|
|
|
|
|
$
|
21.78
|
|
|
|
12/31/2013
|
|
Christopher J. Lindop(3)
|
|
|
5,231
|
|
|
|
18,750
|
|
|
$
|
24.20
|
|
|
|
9/21/2013
|
|
|
|
|
(1) |
|
Unless otherwise noted, options become exercisable in four equal
annual installments beginning on the first anniversary of the
date of grant. |
|
(2) |
|
Unless otherwise noted, the expiration date of each option
occurs 10 years after the date of grant of such option. |
|
(3) |
|
By their terms, the exercisable options were set to expire
90 days after Mr. Lindops last day of employment
with the Company on December 31, 2006. All such options
were exercised prior to expiration. |
16
Option Exercises and Stock Vested. The
following table sets forth certain information with respect to
options exercised by the named executive officers in fiscal year
2006.
Option
Exercises and Stock Vested 2006
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
Number of Shares
|
|
|
Value Realized on
|
|
Name
|
|
Acquired on Exercise (#)
|
|
|
Exercise ($)(1)
|
|
|
Ron Zwanziger
|
|
|
|
|
|
|
|
|
David Teitel
|
|
|
|
|
|
|
|
|
John Bridgen, Ph.D.
|
|
|
|
|
|
|
|
|
David Scott, Ph.D.
|
|
|
|
|
|
|
|
|
David Toohey
|
|
|
|
|
|
|
|
|
Jerry McAleer, Ph.D.
|
|
|
10,000
|
|
|
$
|
255,200
|
|
Christopher J. Lindop
|
|
|
58,454
|
|
|
$
|
826,632
|
|
|
|
|
(1) |
|
Represents the difference between the exercise price and the
fair market value of the common stock on the date of exercise. |
Non-Qualified Defined Contribution and Other Non-Qualified
Deferred Compensation Plans. The following table sets
forth certain information with respect to a named executive
officers participation in a non-qualified defined
contribution plan in fiscal year 2006.
Non-Qualified
Deferred Compensation 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive
|
|
|
Registrant
|
|
|
|
|
|
Aggregate
|
|
|
Aggregate Balance
|
|
|
|
Contributions In
|
|
|
Contributions in
|
|
|
Aggregate Earnings
|
|
|
Withdrawals/
|
|
|
at Last Fiscal
|
|
|
|
Last Fiscal Year
|
|
|
Last Fiscal Year
|
|
|
in Last Fiscal Year
|
|
|
Distributions
|
|
|
Year-End
|
|
Name
|
|
($)
|
|
|
($)(1)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
David Toohey(2)
|
|
$
|
63,824
|
|
|
$
|
63,824
|
|
|
$
|
103,167
|
|
|
|
|
|
|
$
|
873,067
|
|
|
|
|
(1) |
|
This amount is also reported in the All Other
Compensation column of the Summary Compensation Table
above. |
|
(2) |
|
Amounts reported were converted from Euros to U.S. dollars using
the average exchange rate for the year reported. |
Mr. Toohey, who is employed through an Irish subsidiary,
participates in a defined contribution plan which is not a
qualified plan under applicable United States tax
laws. This defined contribution plan, which is also available to
the two other employees of this subsidiary, is approved by the
Irish Revenue Commissioners under the 1997 Taxes Consolidation
Act. Employee contributions under the Irish plan up to
age-determined maximums (based on a percentage of gross salary
ranging from 15% to 40%, depending on age), along with a company
match up to 15% of gross salary, are made free of tax in
Ireland. The amount of gross salary on which contributions are
based is capped at approximately $329,462. Under the Irish plan,
contributions are made to a fund managed by Irish Life. At
retirement participants can elect to take benefits in the form
of: (a) a tax free lump sum cash payment of up to 1.5 times
annual earnings; (b) purchase of an annuity; or (c) in
certain circumstances and subject to limitation, transfer their
account value to another approved retirement fund.
Except for Irish plan described above, our named executive
officers do not participate in any other non-qualified defined
contribution or other deferred compensation plans.
Pension Benefits. Our named executive
officers do not participate in any plan that provides for
specified retirement benefits, or payments and benefits that
will be provided primarily following retirement, other than
defined contribution plans such as our 401(k) savings plan.
17
Potential Payments Upon Termination or
Change-in-Control. Our
named executive officers are
employees-at-will
and as such do not have employment contracts with us. Other than
provisions in our 2001 Stock Option and Incentive Plan that
provide for all stock options to automatically become fully
exercisable and any stock awards to become vested and
non-forfeitable in the event of a change of control
as defined in the plan, there are no contracts, agreements,
plans or arrangements that provide for payments to our named
executive officers at, following, or in connection with any
termination of employment, change in control of our company or a
change in a named executive officers responsibilities.
Director Compensation. The following
table sets forth information regarding the compensation of our
directors during fiscal year 2006.
Director
Compensation 2006
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Total
|
|
Name(1)
|
|
($)(2)
|
|
|
($)
|
|
|
Carol R. Goldberg
|
|
$
|
103,875
|
|
|
$
|
103,875
|
|
Robert P. Khederian
|
|
$
|
103,875
|
|
|
$
|
103,875
|
|
John F. Levy
|
|
$
|
103,875
|
|
|
$
|
103,875
|
|
John A. Quelch
|
|
$
|
116,839
|
|
|
$
|
116,839
|
|
Peter Townsend
|
|
$
|
103,875
|
|
|
$
|
103,875
|
|
Alfred M. Zeien(3)
|
|
$
|
103,875
|
|
|
$
|
103,875
|
|
|
|
|
(1) |
|
Ron Zwanziger, Jerry McAleer and David Scott are not included in
this table as they are employees of our company and accordingly
receive no compensation for their services as directors. The
compensation received by Mr. Zwanziger, Dr. McAleer
and Dr. Scott as employees of our company are shown in the
Summary Compensation Table above. |
|
(2) |
|
The amounts in this column reflect the dollar amount recognized
for financial statement reporting purposes for the fiscal year
ended December 31, 2006, in accordance with FAS 123(R)
from awards granted in 2005 and 2003, as no options were granted
in 2004 or 2006. Assumptions used in the calculation of these
amounts are included in Note 15 of the notes to our audited
consolidated financial statements for the fiscal year ended
December 31, 2006 included in our Annual Report on
Form 10-K/A
filed with the Securities and Exchange Commission on
March 26, 2007. The grant date fair value of the options
granted was as follows for each of the directors: Carol R.
Goldberg: $311,910 (2005); Robert P. Khederian: $311,910 (2005);
John F. Levy: $311,910 (2005); John A. Quelch: $205,920
(2003) and $311,910 (2005); Peter Townsend: $311,910
(2005) and Alfred M. Zeien: $311,910 (2005). As of
December 31, 2006, each director had the following number
of options outstanding: Carol R. Goldberg: 50,000; Robert P.
Khederian: 50,000; John F. Levy: 55,184; John A. Quelch: 50,000;
Peter Townsend: 50,000 and Alfred M. Zeien: 50,000. |
|
(3) |
|
Mr. Zeien resigned as a director on September 27, 2007. |
Our directors currently receive no cash compensation for their
services as directors, although they are reimbursed for expenses
incurred in connection with their attendance at board and
committee meetings. However, options and other awards may be
granted to directors in the sole discretion of the administrator
of the 2001 Stock Option and Incentive Plan. No grants were made
to our directors in fiscal year 2006.
Change-In-Control
Arrangements
There are no compensatory plans or arrangements with any named
executive officer in connection with a change in control of our
company or a change in such officers responsibilities,
except that the 2001 Stock Option and Incentive Plan provides
that in the event of a change of control, as defined
in the plan, all stock options will automatically become fully
exercisable and all other stock awards will automatically become
vested and non-forfeitable.
18
Compensation
Committee Interlocks and Insider Participation
The members of the Compensation Committee for the Companys
2006 fiscal year were Carol R. Goldberg, Chairperson, Alfred M.
Zeien, Member, and Robert P. Khederian, Member. No member of the
Compensation Committee has ever served as an officer or employee
of the Company. No member of the Compensation Committee had any
relationship with the Company requiring disclosure under
Item 404 of
Regulation S-K.
During 2006, no executive officer of the Company served on the
board of directors or compensation committee of another entity
that has or had an executive officer serving as a member of our
Board or Compensation Committee.
EQUITY
COMPENSATION PLAN INFORMATION
The following table furnishes information with respect to
compensation plans under which equity securities of the Company
are authorized for issuance as of December 31, 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of securities
|
|
|
|
|
|
|
|
|
|
remaining available for
|
|
|
|
Number of securities to be
|
|
|
Weighted-average
|
|
|
future issuance under
|
|
|
|
issued upon exercise of
|
|
|
exercise price of
|
|
|
equity compensation plans
|
|
|
|
outstanding options, warrants
|
|
|
outstanding options,
|
|
|
(excluding securities
|
|
|
|
and rights(1)
|
|
|
warrants and rights
|
|
|
reflected in column (a))(2)
|
|
Plan category
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
|
Equity compensation plans approved by security holders
|
|
|
3,444,249
|
|
|
$
|
22.19
|
|
|
|
2,224,977
|
(3)
|
Equity compensation plans not approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
Total(4)
|
|
|
3,444,249
|
|
|
$
|
22.19
|
|
|
|
2,224,977
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
This table excludes an aggregate of 330,241 shares issuable
upon exercise of outstanding options assumed by the Company in
connection with various acquisition transactions. The weighted
average exercise price of the excluded options is $9.77. |
|
(2) |
|
In addition to being available for future issuance upon exercise
of options that may be granted after December 31, 2006,
1,988,726 shares under the 2001 Stock Option Plan may
instead be issued in the form of restricted stock, unrestricted
stock, performance share awards or other equity-based awards. |
|
(3) |
|
Includes 236,251 shares authorized and available for
issuance under the Companys 2001 Employee Stock Purchase
Plan as of December 31, 2006. |
|
(4) |
|
As of November 15, 2007, there was a total of
6,958,122 shares to be issued upon the exercise of
outstanding options at a weighted average exercise price of
$28.80 and an average remaining term of 6.91 years under
all equity compensation plans, including shares issuable upon
exercise of outstanding options assumed by the Company in
connection with various acquisition transactions. Additionally,
on November 16, 2007, we assumed options to purchase
380,894 shares of common stock in connection with our
acquisition of Alere Medical, Inc. As of November 15, 2007,
there were 29,825 shares available for future grant under
the Companys 2001 Stock Option Plan and
174,536 shares available for issuance under the
Companys 2001 Employee Stock Purchase Plan. |
19
Stockholders who wish to present proposals pursuant to
Rule 14a-8
promulgated under the Exchange Act for consideration at our 2008
annual meeting of stockholders must submit the proposals in
proper form to us at the address set forth on the first page of
this proxy statement not later than December 10, 2007 in
order for the proposals to be considered for inclusion in our
proxy statement and form of proxy relating to the 2008 annual
meeting.
Stockholder proposals intended to be presented at our 2008
annual meeting submitted outside the processes of
Rule 14a-8
must be received in writing by us no later than the close of
business on February 15, 2008, nor earlier than
January 18, 2008, together with all supporting
documentation and information required by our bylaws. Proxies
solicited by the Board will confer discretionary voting
authority with respect to these proposals, subject to SEC rules
governing the exercise of this authority.
Our Nominating and Corporate Governance Committee will consider
director candidates recommended for nomination by stockholders.
There are no differences in the manner in which the Nominating
and Corporate Governance Committee evaluates nominees for
director based on whether the nominee is recommended by a
stockholder. In order to have a director candidate considered by
the Nominating and Corporate Governance Committee, the
recommendation must be submitted to the Company Secretary at the
address set forth on the first page of this proxy statement not
later than December 5, 2007 and must include: the name and
address of record of the stockholder; a representation that the
stockholder is a record holder of our voting stock, or if the
stockholder is not a record hold of our voting stock, evidence
of ownership in accordance with
Rule 14a-8(b)(2)
of the Exchange Act; the name, age, business and residential
address, educational background, current principal occupation or
employment, and principal occupation or employment for the
preceding five (5) full fiscal years of the proposed
director candidate; a description of the qualifications and
background of the proposed director candidate which addresses
the minimum qualifications and other criteria for Board
membership approved by the Board from time to time; a
description of all arrangements or understandings between the
stockholder and the proposed director candidate; the consent of
the proposed director candidate (i) to be named in the
proxy statement relating to the our annual meeting of
stockholders and (ii) to serve as a director if elected at
such annual meeting; and any other information regarding the
proposed director candidate that is required to be included in a
proxy statement filed pursuant to the rules of the Securities
and Exchange Commission.
A copy of our Annual Report on
Form 10-K/A,
including the financial statements and the financial statement
schedules, for the year ended December 31, 2006 (the
Annual Report) shall be provided without charge to
each person solicited hereby upon the written request made
to:
Inverness
Medical Innovations, Inc.
Investor
Relations Department
51 Sawyer Road
Suite 200
Waltham, MA
02453-3448
Attn: Doug Guarino
In addition, copies of any exhibits to the Annual Report will
be provided for a nominal charge to stockholders who make a
written request to us at the above address.
20
Appendix A
EXPLANATORY NOTE: This Appendix A
contains a copy of the Inverness Medical Innovations, Inc. 2001
Stock Option and Incentive Plan, as amended by the proposed
amendment described in the proxy statement to which this
Appendix A is attached.
INVERNESS
MEDICAL INNOVATIONS, INC.
2001
STOCK OPTION AND INCENTIVE PLAN
Section 1. GENERAL
PURPOSE OF THE PLAN; DEFINITIONS
The name of the plan is the Inverness Medical Innovations, Inc.
2001 Stock Option and Incentive Plan (the Plan). The
purpose of the Plan is to encourage and enable the officers,
employees, Independent Directors and other key persons
(including consultants) of Inverness Medical Innovations, Inc.
(the Company) and its Subsidiaries upon whose
judgment, initiative and efforts the Company largely depends for
the successful conduct of its business to acquire a proprietary
interest in the Company. It is anticipated that providing such
persons with a direct stake in the Companys welfare will
assure a closer identification of their interests with those of
the Company, thereby stimulating their efforts on the
Companys behalf and strengthening their desire to remain
with the Company.
The following terms shall be defined as set forth below:
Act means the Securities Act of 1933, as
amended, and the rules and regulations thereunder.
Administrator is defined in Section 2(a).
Award or Awards, except
where referring to a particular category of grant under the
Plan, shall include Incentive Stock Options, Non-Qualified Stock
Options, Deferred Stock Awards, Restricted Stock Awards,
Unrestricted Stock Awards, Performance Share Awards and Dividend
Equivalent Rights.
Board means the Board of Directors of the
Company.
Change of Control is defined in
Section 15.
Code means the Internal Revenue Code of 1986,
as amended, and any successor Code, and related rules,
regulations and interpretations.
Committee means the Committee of the Board
referred to in Section 2.
Covered Employee means an employee who is a
Covered Employee within the meaning of
Section 162(m) of the Code.
Deferred Stock Award means Awards granted
pursuant to Section 7.
Dividend Equivalent Right means Awards
granted pursuant to Section 10.
Effective Date means the date on which the
Plan is approved by stockholders as set forth in Section 17.
Exchange Act means the Securities Exchange
Act of 1934, as amended, and the rules and regulations
thereunder.
Fair Market Value of the Stock on any given
date means the fair market value of the Stock determined in good
faith by the Administrator; provided, however, that if the Stock
is admitted to quotation on the National Association of
Securities Dealers Automated Quotation System
(NASDAQ) or a national securities exchange, the
determination shall be made by reference to market quotations.
If there are no market quotations for such date, the
determination shall be made by reference to the last date
preceding such date for which there are market quotations.
A-1
Incentive Stock Option means any Stock Option
designated and qualified as an incentive stock
option as defined in Section 422 of the Code.
Independent Director means a member of the
Board who is not also an employee of the Company or any
Subsidiary.
Non-Qualified Stock Option means any Stock
Option that is not an Incentive Stock Option.
Option or Stock Option
means any option to purchase shares of Stock granted
pursuant to Section 5.
Performance Share Award means Awards granted
pursuant to Section 9.
Restricted Stock Award means Awards granted
pursuant to Section 6.
Stock means the Common Stock, par value
$0.001 per share, of the Company, subject to adjustments
pursuant to Section 3.
Subsidiary means any corporation or other
entity (other than the Company) in which the Company has a
controlling interest, either directly or indirectly.
Unrestricted Stock Award means any Award
granted pursuant to Section 8.
|
|
Section 2. |
ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT
GRANTEES AND DETERMINE AWARDS
|
(a) Committee. The Plan shall be
administered by either the Board or a committee of not less than
two Independent Directors (in either case, the
Administrator), as determined by the Board from time
to time; provided that, for purposes of Awards to
Directors or Section 16 officers of the Company, the
Administrator shall be deemed to include only Directors who are
Independent Directors and no director who is not an Independent
Director shall be entitled to vote or take action in connection
with any such proposed Award.
(b) Powers of Administrator. The
Administrator shall have the power and authority to grant Awards
consistent with the terms of the Plan, including the power and
authority:
(i) to select the individuals to whom Awards may from time
to time be granted;
(ii) to determine the time or times of grant, and the
extent, if any, of Incentive Stock Options, Non-Qualified Stock
Options, Restricted Stock Awards, Deferred Stock Awards,
Unrestricted Stock Awards, Performance Share Awards and Dividend
Equivalent Rights or any combination of the foregoing, granted
to any one or more grantees;
(iii) to determine the number of shares of Stock to be
covered by any Award;
(iv) to determine and modify from time to time the terms
and conditions, including restrictions, not inconsistent with
the terms of the Plan and Section 2(b)(v) below, of any
Award, which terms and conditions may differ among individual
Awards and grantees, and to approve the form of written
instruments evidencing the Awards; except that repricing of
Stock Options shall not be permitted without shareholder
approval and further provided that, other than by reason of, or
in connection with, any death, disability, retirement,
employment termination (without cause), or Change of
Control, the Administrator shall not accelerate or waive
any restriction period applicable to any outstanding Restricted
Stock Award or any Deferred Stock Award beyond the minimum
restriction periods set forth in Section 6(e) and
Section 7(d), respectively, nor shall the Administrator
accelerate or amend the aggregate period over which any
Performance Share Award is measured to less than one
(1) year;
(v) to accelerate at any time the exercisability or vesting
of all or any portion of any Award consistent with
Section 2(b)(iv) and further provided that, other than by
reason of, or in connection with, any death, disability,
retirement, employment termination (without cause), or Change of
Control, the Administrator shall not accelerate the
exercisability or vesting of unvested Stock Options which in the
aggregate, when combined with the aggregate number of shares of
Stock issued pursuant to Section 8, exceed ten percent
(10%) of the maximum number of shares of stock reserved and
available for issuance under the Plan pursuant to
Section 3(a), as amended;
A-2
(vi) subject to the provisions of Section 5(a)(ii), to
extend at any time the period in which Stock Options may be
exercised;
(vii) to determine at any time whether, to what extent, and
under what circumstances distribution or the receipt of Stock
and other amounts payable with respect to an Award shall be
deferred either automatically or at the election of the grantee
and whether and to what extent the Company shall pay or credit
amounts constituting interest (at rates determined by the
Administrator) or dividends or deemed dividends on such
deferrals; and
(viii) at any time to adopt, alter and repeal such rules,
guidelines and practices for administration of the Plan and for
its own acts and proceedings as it shall deem advisable; to
interpret the terms and provisions of the Plan and any Award
(including related written instruments); to make all
determinations it deems advisable for the administration of the
Plan; to decide all disputes arising in connection with the
Plan; and to otherwise supervise the administration of the Plan.
All decisions and interpretations of the Administrator shall be
binding on all persons, including the Company and Plan grantees.
(c) Delegation of Authority to Grant
Awards. The Administrator, in its discretion,
may delegate to the Chief Executive Officer of the Company all
or part of the Administrators authority and duties with
respect to the granting of Awards at Fair Market Value, to
individuals who are not subject to the reporting and other
provisions of Section 16 of the Exchange Act or Covered
Employees. Any such delegation by the Administrator shall
include a limitation as to the amount of Awards that may be
granted during the period of the delegation and shall contain
guidelines as to the determination of the exercise price of any
Stock Option, the conversion ratio or price of other Awards and
the vesting criteria. The Administrator may revoke or amend the
terms of a delegation at any time but such action shall not
invalidate any prior actions of the Administrators
delegate or delegates that were consistent with the terms of the
Plan.
(d) Indemnification. Neither the
Board nor the Committee, nor any member of either or any
delegatee thereof, shall be liable for any act, omission,
interpretation, construction or determination made in good faith
in connection with the Plan, and the members of the Board and
the Committee (and any delegatee thereof) shall be entitled in
all cases to indemnification and reimbursement by the Company in
respect of any claim, loss, damage or expense (including,
without limitation, reasonable attorneys fees) arising or
resulting therefrom to the fullest extent permitted by law
and/or under
any directors and officers liability insurance
coverage which may be in effect from time to time.
Section 3. STOCK
ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION
(a) Stock Issuable. The maximum
number of shares of Stock reserved and available for issuance
under the Plan shall be 11,074,081 shares, subject to
adjustment as provided in Section 3(b) (the
Pool). For purposes of this limitation, in respect
of any shares of Stock under any Award which shares are
forfeited, canceled, satisfied without the issuance of Stock,
otherwise terminated, or, for shares of Stock issued pursuant to
any unvested full value Award, reacquired by the Company at not
more than the grantees purchase price (other than by
exercise) (Unissued Shares), the number of shares of
Stock that were removed from the Pool for such Unissued Shares
shall be added back to the Pool. Notwithstanding the foregoing,
upon the exercise of any Award to the extent that the Award is
exercised through tendering previously owned shares or through
withholding shares that would otherwise be awarded and to the
extent shares are withheld for tax withholding purposes, the
Pool shall be reduced by the gross number of shares of Stock
being exercised without giving effect to the number of shares
tendered or withheld. Subject to such overall limitation, shares
of Stock may be issued up to such maximum number pursuant to any
type or types of Award; provided, however, (i) Stock
Options with respect to no more than 1,529,632 shares of
Stock may be granted to any one individual grantee during any
one calendar year period and (ii) each share subject to a
full value award settled in stock other than an
Award that is a stock option or other award that requires the
grantee to purchase shares for their fair market value at the
time of grant will reduce the number of shares in
the Pool available for grant by three (3). The shares available
for issuance from the Pool may be authorized but unissued shares
of Stock or shares of Stock or shares of Stock reacquired by the
Company and held in its treasury.
A-3
(b) Changes in Stock. Subject to
Section 3(c) hereof, if, as a result of any reorganization,
recapitalization, reclassification, stock dividend, stock split,
reverse stock split or other similar change in the
Companys capital stock, the outstanding shares of Stock
are increased or decreased or are exchanged for a different
number or kind of shares or other securities of the Company, or
additional shares or new or different shares or other securities
of the Company or other non-cash assets are distributed with
respect to such shares of Stock or other securities, or, if, as
a result of any merger or consolidation, sale of all or
substantially all of the assets of the Company, the outstanding
shares of Stock are converted into or exchanged for a different
number or kind of securities of the Company or any successor
entity (or a parent or subsidiary thereof), the Administrator
shall make an appropriate or proportionate adjustment in
(i) the maximum number of shares reserved for issuance
under the Plan, (ii) the number of Stock Options that can
be granted to any one individual grantee, (iii) the number
and kind of shares or other securities subject to any then
outstanding Awards under the Plan, (iv) the repurchase
price per share subject to each outstanding Restricted Stock
Award, and (v) the price for each share subject to any then
outstanding Stock Options under the Plan, without changing the
aggregate exercise price (i.e., the exercise price multiplied by
the number of Stock Options) as to which such Stock Options
remain exercisable. The adjustment by the Administrator shall be
final, binding and conclusive. No fractional shares of Stock
shall be issued under the Plan resulting from any such
adjustment, but the Administrator in its discretion may make a
cash payment in lieu of fractional shares.
The Administrator may also adjust the number of shares subject
to outstanding Awards and the exercise price and the terms of
outstanding Awards to take into consideration material changes
in accounting practices or principles, extraordinary dividends,
acquisitions or dispositions of stock or property or any other
event if it is determined by the Administrator that such
adjustment is appropriate to avoid distortion in the operation
of the Plan, provided that no such adjustment shall be made in
the case of an Incentive Stock Option, without the consent of
the grantee, if it would constitute a modification, extension or
renewal of the Option within the meaning of Section 424(h)
of the Code.
(c) Mergers and Other
Transactions. In the case of and subject to
the consummation of (i) the dissolution or liquidation of
the Company, (ii) the sale of all or substantially all of
the assets of the Company on a consolidated basis to an
unrelated person or entity, (iii) a merger, reorganization
or consolidation in which the outstanding shares of Stock are
converted into or exchanged for a different kind of securities
of the successor entity and the holders of the Companys
outstanding voting power immediately prior to such transaction
do not own a majority of the outstanding voting power of the
successor entity immediately upon completion of such
transaction, or (iv) the sale of all of the Stock of the
Company to an unrelated person or entity (in each case, a
Sale Event), upon the effective time of the Sale
Event, the Plan and all outstanding Awards granted hereunder
shall terminate, unless provision is made in connection with the
Sale Event in the sole discretion of the parties thereto for the
assumption or continuation of Awards theretofore granted by the
successor entity, or the substitution of such Awards with new
Awards of the successor entity or parent thereof, with
appropriate adjustment as to the number and kind of shares and,
if appropriate, the per share exercise prices, as such parties
shall agree (after taking into account any acceleration
hereunder). In the event of such termination, each grantee shall
be permitted, within a specified period of time prior to the
consummation of the Sale Event as determined by the
Administrator, to exercise all outstanding Options held by such
grantee, including those that will become exercisable upon the
consummation of the Sale Event; provided, however, that the
exercise of Options not exercisable prior to the Sale Event
shall be subject to the consummation of the Sale Event.
Notwithstanding anything to the contrary in this
Section 3(c), in the event of a Sale Event pursuant to
which holders of the Stock of the Company will receive upon
consummation thereof a cash payment for each share surrendered
in the Sale Event, the Company shall have the right, but not the
obligation, to make or provide for a cash payment to the
grantees holding Options, in exchange for the cancellation
thereof, in an amount equal to the difference between
(A) the value as determined by the Administrator of the
consideration payable per share of Stock pursuant to the Sale
Event (the Sale Price) times the number of shares of
Stock subject to outstanding Options (to the extent then
exercisable at prices not in excess of the Sale Price) and
(B) the aggregate exercise price of all such outstanding
Options.
A-4
(d) Substitute Awards. The
Administrator may grant Awards under the Plan in substitution
for stock and stock based awards held by employees, directors or
other key persons of another corporation in connection with the
merger or consolidation of the employing corporation with the
Company or a Subsidiary or the acquisition by the Company or a
Subsidiary of property or stock of the employing corporation.
The Administrator may direct that the substitute awards be
granted on such terms and conditions as the Administrator
considers appropriate in the circumstances. Any substitute
Awards granted under the Plan shall not count against the share
limitation set forth in Section 3(a).
Section 4. ELIGIBILITY
Grantees under the Plan will be such full or part-time officers
and other employees, Independent Directors and key persons
(including consultants and prospective employees) of the Company
and its Subsidiaries as are selected from time to time by the
Administrator in its sole discretion.
Section 5. STOCK
OPTIONS
Any Stock Option granted under the Plan shall be in such form as
the Administrator may from time to time approve.
Stock Options granted under the Plan may be either Incentive
Stock Options or Non-Qualified Stock Options. Incentive Stock
Options may be granted only to employees of the Company or any
Subsidiary that is a subsidiary corporation within
the meaning of Section 424(f) of the Code. To the extent
that any Option does not qualify as an Incentive Stock Option,
it shall be deemed a Non-Qualified Stock Option.
No Incentive Stock Option shall be granted under the Plan after
August 14, 2011.
(a) Stock Options. Stock Options
granted pursuant to this Section 5(a) shall be subject to
the following terms and conditions and shall contain such
additional terms and conditions, not inconsistent with the terms
of the Plan, as the Administrator shall deem desirable. If the
Administrator so determines, Stock Options may be granted in
lieu of cash compensation at the optionees election,
subject to such terms and conditions as the Administrator may
establish.
(i) Exercise Price. The exercise
price per share for the Stock covered by a Stock Option granted
pursuant to this Section 5(a) shall be determined by the
Administrator at the time of grant but shall not be less than
100 percent of the Fair Market Value on the date of grant.
If an employee owns or is deemed to own (by reason of the
attribution rules of Section 424(d) of the Code) more than
10 percent of the combined voting power of all classes of
stock of the Company or any parent or subsidiary corporation and
an Incentive Stock Option is granted to such employee, the
option price of such Incentive Stock Option shall be not less
than 110 percent of the Fair Market Value on the grant date.
(ii) Option Term. The term of each
Stock Option shall be fixed by the Administrator, but no Stock
Option shall be exercisable more than 10 years after the
date the Stock Option is granted. If an employee owns or is
deemed to own (by reason of the attribution rules of
Section 424(d) of the Code) more than 10 percent of
the combined voting power of all classes of stock of the Company
or any parent or subsidiary corporation and an Incentive Stock
Option is granted to such employee, the term of such Stock
Option shall be no more than five years from the date of grant.
(iii) Exercisability; Rights of a
Stockholder. Stock Options shall become
exercisable at such time or times, whether or not in
installments, as shall be determined by the Administrator at or
after the grant date. Subject to Section 2(b)(v), the
Administrator may at any time accelerate the exercisability of
all or any portion of any Stock Option. An optionee shall have
the rights of a stockholder only as to shares acquired upon the
exercise of a Stock Option and not as to unexercised Stock
Options.
(iv) Method of Exercise. Stock
Options may be exercised in whole or in part, by giving written
notice of exercise to the Company, specifying the number of
shares to be purchased. Payment of the purchase price may be
made by one or more of the following methods to the extent
provided in the Option Award agreement:
(A) In cash, by certified or bank check or other instrument
acceptable to the Administrator;
A-5
(B) Through the delivery (or attestation to the ownership)
of shares of Stock that have been purchased by the optionee on
the open market or that have been beneficially owned by the
optionee for at least six months and are not then subject to
restrictions under any Company plan. Such surrendered shares
shall be valued at Fair Market Value on the exercise date;
(C) By the optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions
to a broker to promptly deliver to the Company cash or a check
payable and acceptable to the Company for the purchase price;
provided that in the event the optionee chooses to pay the
purchase price as so provided, the optionee and the broker shall
comply with such procedures and enter into such agreements of
indemnity and other agreements as the Administrator shall
prescribe as a condition of such payment procedure; or
(D) Any other method permitted by the Administrator.
Payment instruments will be received subject to collection. The
delivery of certificates representing the shares of Stock to be
purchased pursuant to the exercise of a Stock Option will be
contingent upon receipt from the optionee (or a purchaser acting
in his stead in accordance with the provisions of the Stock
Option) by the Company of the full purchase price for such
shares and the fulfillment of any other requirements contained
in the Option Award agreement or applicable provisions of laws.
In the event an optionee chooses to pay the purchase price by
previously-owned shares of Stock through the attestation method,
the number of shares of Stock transferred to the optionee upon
the exercise of the Stock Option shall be net of the number of
shares attested to.
(v) Annual Limit on Incentive Stock
Options. To the extent required for
incentive stock option treatment under
Section 422 of the Code, the aggregate Fair Market Value
(determined as of the time of grant) of the shares of Stock with
respect to which Incentive Stock Options granted under this Plan
and any other plan of the Company or its parent and subsidiary
corporations become exercisable for the first time by an
optionee during any calendar year shall not exceed $100,000. To
the extent that any Stock Option exceeds this limit, it shall
constitute a Non-Qualified Stock Option.
(b) Reload Options. At the
discretion of the Administrator, Options granted under the Plan
may include a reload feature pursuant to which an
optionee exercising an option by the delivery of a number of
shares of Stock in accordance with Section 5(a)(iv)(B)
hereof would automatically be granted an additional Option (with
an exercise price equal to the Fair Market Value of the Stock on
the date the additional Option is granted and with such other
terms as the Administrator may provide) to purchase that number
of shares of Stock equal to the sum of (i) the number
delivered to exercise the original Option and (ii) the
number withheld to satisfy tax liabilities, with an Option term
equal to the remainder of the original Option term unless the
Administrator otherwise determines in the Award agreement for
the original Option grant.
(c) Non-transferability of
Options. No Stock Option shall be
transferable by the optionee otherwise than by will or by the
laws of descent and distribution and all Stock Options shall be
exercisable, during the optionees lifetime, only by the
optionee, or by the optionees legal representative or
guardian in the event of the optionees incapacity.
Notwithstanding the foregoing, the Administrator, in its sole
discretion, may provide in the Award agreement regarding a given
Option that the optionee may transfer his Non-Qualified Stock
Options to members of his immediate family, to trusts for the
benefit of such family members, or to partnerships in which such
family members are the only partners, provided that the
transferee agrees in writing with the Company to be bound by all
of the terms and conditions of this Plan and the applicable
Option.
(d) Form of Settlement. Shares of
Stock issued upon exercise of a Stock Option shall be free of
all restrictions under the Plan, except as otherwise provided in
the Plan.
Section 6. RESTRICTED
STOCK AWARDS
(a) Nature of Restricted Stock
Awards. A Restricted Stock Award is an Award
entitling the recipient to acquire, at such purchase price as
determined by the Administrator, shares of Stock subject to such
restrictions and conditions as the Administrator may determine
at the time of grant (Restricted Stock). Conditions
may be based on continuing employment (or other service
relationship)
and/or
achievement of pre-established
A-6
performance goals and objectives. The grant of a Restricted
Stock Award is contingent on the grantee executing the
Restricted Stock Award agreement. The terms and conditions of
each such agreement shall be determined by the Administrator,
and such terms and conditions may differ among individual Awards
and grantees.
(b) Rights as a Stockholder. Upon
execution of a written instrument setting forth the Restricted
Stock Award and payment of any applicable purchase price, a
grantee shall have the rights of a stockholder with respect to
the voting of the Restricted Stock, subject to such conditions
contained in the written instrument evidencing the Restricted
Stock Award. Unless the Administrator shall otherwise determine,
certificates evidencing the Restricted Stock shall remain in the
possession of the Company until such Restricted Stock is vested
as provided in Section 6(d) below, and the grantee shall be
required, as a condition of the grant, to deliver to the Company
a stock power endorsed in blank.
(c) Restrictions. Restricted Stock
may not be sold, assigned, transferred, pledged or otherwise
encumbered or disposed of except as specifically provided herein
or in the Restricted Stock Award agreement. If a grantees
employment (or other service relationship) with the Company and
its Subsidiaries terminates for any reason, the Company shall
have the right to repurchase Restricted Stock that has not
vested at the time of termination at its original purchase
price, from the grantee or the grantees legal
representative.
(d) Vesting of Restricted
Stock. The Administrator at the time of grant
shall specify the date or dates
and/or the
attainment of pre-established performance goals, objectives and
other conditions on which the
non-transferability
of the Restricted Stock and the Companys right of
repurchase or forfeiture shall lapse. Subsequent to such date or
dates and/or
the attainment of such pre-established performance goals,
objectives and other conditions, the shares on which all
restrictions have lapsed shall no longer be Restricted Stock and
shall be deemed vested. Except as may otherwise be
provided by the Administrator either in the Award agreement or,
subject to Section 13 below, in writing after the Award
agreement is issued, a grantees rights in any shares of
Restricted Stock that have not vested shall automatically
terminate upon the grantees termination of employment (or
other service relationship) with the Company and its
Subsidiaries and such shares shall be subject to the
Companys right of repurchase as provided in
Section 6(c) above.
(e) Restriction Period. Restricted
Stock vesting upon the attainment of performance goals or
objectives shall vest after a restriction period of not less
than one (1) year. All other Restricted Stock shall vest
after a restriction period of not less than three (3) years.
(f) Waiver, Deferral and Reinvestment of
Dividends. The Restricted Stock Award
agreement may require or permit the immediate payment, waiver,
deferral or investment of dividends paid on the Restricted Stock.
Section 7. DEFERRED
STOCK AWARDS
(a) Nature of Deferred Stock
Awards. A Deferred Stock Award is an Award of
phantom stock units to a grantee, subject to restrictions and
conditions as the Administrator may determine at the time of
grant. Conditions may be based on continuing employment (or
other service relationship)
and/or
achievement of pre-established performance goals and objectives.
The grant of a Deferred Stock Award is contingent on the grantee
executing the Deferred Stock Award agreement. The terms and
conditions of each such agreement shall be determined by the
Administrator, and such terms and conditions may differ among
individual Awards and grantees. At the end of the deferral
period, the Deferred Stock Award, to the extent vested, shall be
paid to the grantee in the form of shares of Stock.
(b) Election to Receive Deferred Stock Awards in Lieu
of Compensation. The Administrator may, in
its sole discretion, permit a grantee to elect to receive a
portion of the cash compensation or Restricted Stock Award
otherwise due to such grantee in the form of a Deferred Stock
Award. Any such election shall be made in writing and shall be
delivered to the Company no later than the date specified by the
Administrator and in accordance with rules and procedures
established by the Administrator. The Administrator shall have
the sole right to determine whether and under what circumstances
to permit such elections and to impose such limitations and
other terms and conditions thereon as the Administrator deems
appropriate.
A-7
(c) Rights as a
Stockholder. During the deferral period, a
grantee shall have no rights as a stockholder; provided,
however, that the grantee may be credited with Dividend
Equivalent Rights with respect to the phantom stock units
underlying his Deferred Stock Award, subject to such terms and
conditions as the Administrator may determine.
(d) Restrictions. Deferred Stock
Awards vesting upon the attainment of performance goals or
objectives shall vest after a restriction period of not less
than one (1) year. All other Deferred Stock Awards shall
vest after a restriction period of not less than three
(3) years. A Deferred Stock Award may not be sold,
assigned, transferred, pledged or otherwise encumbered or
disposed of during the deferral period.
(e) Termination. Except as may
otherwise be provided by the Administrator either in the Award
agreement or, subject to Section 13 below, in writing after
the Award agreement is issued, a grantees right in all
Deferred Stock Awards that have not vested shall automatically
terminate upon the grantees termination of employment (or
cessation of service relationship) with the Company and its
Subsidiaries for any reason.
Section 8. UNRESTRICTED
STOCK AWARDS
(a) Grant or Sale of Unrestricted
Stock. The Administrator may, in its sole
discretion, grant (or sell at a purchase price determined by the
Administrator) an Unrestricted Stock Award to any grantee,
pursuant to which such grantee may receive shares of Stock free
of any restrictions (Unrestricted Stock) under the
Plan. Unrestricted Stock Awards may be granted or sold as
described in the preceding sentence in respect of past services
or other valid consideration, or in lieu of any cash
compensation due to such participant. The aggregate number of
shares of Stock issuable pursuant to this Section 8, when
combined with the number of shares of underlying unvested Stock
Options accelerated pursuant to Section 2(b)(v) other
than by reason of, or in connection with, any death, disability,
retirement, employment termination, or Change of Control, is
limited to ten percent (10%) of the maximum number of shares of
Stock reserved and available for issuance under the Plan
pursuant to Section 3(a), as amended.
(b) Elections to Receive Unrestricted Stock in Lieu
of Compensation. Upon the request of a
grantee and with the consent of the Administrator, each grantee
may, pursuant to an advance written election delivered to the
Company no later than the date specified by the Administrator,
receive a portion of the cash compensation otherwise due to such
grantee in the form of shares of Unrestricted Stock (valued at
Fair Market Value on the date or dates the cash compensation
would otherwise be paid) either currently or on a deferred basis.
(c) Restrictions on Transfers. The
right to receive shares of Unrestricted Stock on a deferred
basis may not be sold, assigned, transferred, pledged or
otherwise encumbered, other than by will or the laws of descent
and distribution.
Section 9. PERFORMANCE
SHARE AWARDS
(a) Nature of Performance Share
Awards. A Performance Share Award is an Award
entitling the recipient to acquire shares of Stock upon the
attainment of specified performance goals. The Administrator may
make Performance Share Awards independent of or in connection
with the granting of any other Award under the Plan. The
Administrator in its sole discretion shall determine whether and
to whom Performance Share Awards shall be made, the performance
goals, the periods during which performance is to be measured
(which in the aggregate shall not be less than one
(1) year), and all other limitations and conditions.
(b) Restrictions of
Transfer. Performance Share Awards, and all
rights with respect to such Awards may not be sold, assigned,
transferred, pledged or otherwise encumbered.
(c) Rights as a Stockholder. A
grantee receiving a Performance Share Award shall have the
rights of a stockholder only as to shares actually received by
the grantee under the Plan and not with respect to shares
subject to the Award but not actually received by the grantee. A
grantee shall be entitled to receive a stock certificate
evidencing the acquisition of shares of Stock under a
Performance Share Award only upon satisfaction of all conditions
specified in the Performance Share Award agreement (or in a
performance plan adopted by the Administrator).
A-8
(d) Termination. Except as may
otherwise be provided by the Administrator either in the Award
agreement or, subject to Section 13 below, in writing after
the Award agreement is issued, a grantees rights in all
Performance Share Awards shall automatically terminate upon the
grantees termination of employment (or cessation of
service relationship) with the Company and its Subsidiaries for
any reason.
Section 10. DIVIDEND
EQUIVALENT RIGHTS
(a) Dividend Equivalent Rights. A
Dividend Equivalent Right is an Award entitling the recipient to
receive credits based on cash dividends that would be paid on
the shares of Stock specified in the Dividend Equivalent Right
(or other award to which it relates) if such shares were held by
the recipient. A Dividend Equivalent Right may be granted
hereunder to any participant, as a component of another Award or
as a freestanding award. The terms and conditions of Dividend
Equivalent Rights shall be specified in the grant. Dividend
equivalents credited to the holder of a Dividend Equivalent
Right may be paid currently or may be deemed to be reinvested in
additional shares of Stock, which may thereafter accrue
additional equivalents. Any such reinvestment shall be at Fair
Market Value on the date of reinvestment or such other price as
may then apply under a dividend reinvestment plan sponsored by
the Company, if any. Dividend Equivalent Rights may be settled
in cash or shares of Stock or a combination thereof, in a single
installment or installments. A Dividend Equivalent Right granted
as a component of another Award may provide that such Dividend
Equivalent Right shall be settled upon exercise, settlement, or
payment of, or lapse of restrictions on, such other award, and
that such Dividend Equivalent Right shall expire or be forfeited
or annulled under the same conditions as such other award. A
Dividend Equivalent Right granted as a component of another
Award may also contain terms and conditions different from such
other award.
(b) Interest Equivalents. Any
Award under this Plan that is settled in whole or in part in
cash on a deferred basis may provide in the grant for interest
equivalents to be credited with respect to such cash payment.
Interest equivalents may be compounded and shall be paid upon
such terms and conditions as may be specified by the grant.
Section 11. TAX
WITHHOLDING
(a) Payment by Grantee. Each
grantee shall, no later than the date as of which the value of
an Award or of any Stock or other amounts received thereunder
first becomes includable in the gross income of the grantee for
Federal income tax purposes, pay to the Company, or make
arrangements satisfactory to the Administrator regarding payment
of, any Federal, state, or local taxes of any kind required by
law to be withheld with respect to such income. The Company and
its Subsidiaries shall, to the extent permitted by law, have the
right to deduct any such taxes from any payment of any kind
otherwise due to the grantee. The Companys obligation to
deliver stock certificates to any grantee is subject to and
conditioned on tax obligations being satisfied by the grantee.
The Companys obligation to deliver stock certificates to
any grantee is subject to and is conditioned on tax obligations
being satisfied by the grantee.
(b) Payment in Stock. Subject to
approval by the Administrator, a grantee may elect to have the
minimum required tax withholding obligation satisfied, in whole
or in part, by (i) authorizing the Company to withhold from
shares of Stock to be issued pursuant to any Award a number of
shares with an aggregate Fair Market Value (as of the date the
withholding is effected) that would satisfy the withholding
amount due, or (ii) transferring to the Company shares of
Stock owned by the grantee with an aggregate Fair Market Value
(as of the date the withholding is effected) that would satisfy
the withholding amount due.
Section 12. TRANSFER,
LEAVE OF ABSENCE, ETC.
For purposes of the Plan, the following events shall not be
deemed a termination of employment:
(a) a transfer to the employment of the Company from a
Subsidiary or from the Company to a Subsidiary, or from one
Subsidiary to another; or
(b) an approved leave of absence for military service or
sickness, or for any other purpose approved by the Company, if
the employees right to re-employment is guaranteed either
by a statute or by contract or under the policy pursuant to
which the leave of absence was granted or if the Administrator
otherwise so provides in writing.
A-9
Section 13. AMENDMENTS
AND TERMINATION
Subject to requirements of law or any stock exchange or other
similar rules which would require a vote of the Companys
shareholders, the Board may, at any time, amend or discontinue
the Plan and the Administrator may, at any time, amend or cancel
any outstanding Award for the purpose of satisfying changes in
law or for any other lawful purpose, but no such action shall
adversely affect rights under any outstanding Award without the
holders consent. If and to the extent determined by the
Administrator to be required by the Code to ensure that
Incentive Stock Options granted under the Plan are qualified
under Section 422 of the Code or to ensure that
compensation earned under Awards qualifies as performance-based
compensation under Section 162(m) of the Code, if and to
the extent intended to so qualify, Plan amendments shall be
subject to approval by the Company stockholders entitled to vote
at a meeting of stockholders. Nothing in this Section 13
shall limit the Administrators authority to take any
action permitted pursuant to Section 3(c).
Section 14. STATUS
OF PLAN
With respect to the portion of any Award that has not been
exercised and any payments in cash, Stock or other consideration
not received by a grantee, a grantee shall have no rights
greater than those of a general creditor of the Company unless
the Administrator shall otherwise expressly determine in
connection with any Award or Awards. In its sole discretion, the
Administrator may authorize the creation of trusts or other
arrangements to meet the Companys obligations to deliver
Stock or make payments with respect to Awards hereunder,
provided that the existence of such trusts or other arrangements
is consistent with the foregoing sentence.
Section 15. CHANGE
OF CONTROL PROVISIONS
Upon the occurrence of a Change of Control as defined in this
Section 15:
(a) Each outstanding Stock Option shall automatically
become fully exercisable.
(b) Except as otherwise provided in the applicable Award
Agreement, conditions and restrictions on each outstanding
Restricted Stock Award, Deferred Stock Award and Performance
Share Award will be removed.
(c) Change of Control shall mean the
occurrence of any one of the following events:
(i) any Person, as such term is used in
Sections 13(d) and 14(d) of the Act (other than the
Company, any of its Subsidiaries, or any trustee, fiduciary or
other person or entity holding securities under any employee
benefit plan or trust of the Company or any of its
Subsidiaries), together with all affiliates and
associates (as such terms are defined in
Rule 12b-2
under the Exchange Act) of such person, shall become the
beneficial owner (as such term is defined in
Rule 13d-3
under the Exchange Act), directly or indirectly, of securities
of the Company representing in excess of 50% of either
(A) the combined voting power of the Companys then
outstanding securities having the right to vote in an election
of the Companys Board of Directors (Voting
Securities) or (B) the then outstanding shares of
Stock of the Company (in either such case other than as a result
of an acquisition of securities directly from the
Company); or
(ii) persons who, as of the Effective Date, constitute the
Companys Board of Directors (the Incumbent
Directors) cease for any reason, including, without
limitation, as a result of a tender offer, proxy contest, merger
or similar transaction, to constitute at least a majority of the
Board, provided that any person becoming a director of the
Company subsequent to the Effective Date shall be considered an
Incumbent Director if such persons election was approved
by or such person was nominated for election by either
(A) a vote of at least a majority of the Incumbent
Directors or (B) a vote of at least a majority of the
Incumbent Directors who are members of a nominating committee
comprised, in the majority, of Incumbent Directors; but provided
further, that any such person whose initial assumption of office
is in connection with an actual or threatened election contest
relating to the election of members of the Board of Directors or
other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Board, including by
reason of
A-10
agreement intended to avoid or settle any such actual or
threatened contest or solicitation, shall not be considered an
Incumbent Director; or
(iii) the consummation of a consolidation, merger or
consolidation or sale or other disposition of all or
substantially all of the assets of the Company (a
Corporate Transaction); excluding, however, a
Corporate Transaction in which the stockholders of the Company
immediately prior to the Corporate Transaction, would,
immediately after the Corporate Transaction, beneficially own
(as such term is defined in
Rule 13d-3
under the Act), directly or indirectly, shares representing in
the aggregate more than 80% of the voting shares of the
corporation issuing cash or securities in the Corporate
Transaction (or of its ultimate parent corporation, if
any); or
(iv) the approval by the stockholders of any plan or
proposal for the liquidation or dissolution of the Company.
Notwithstanding the foregoing, a Change of Control
shall not be deemed to have occurred for purposes of the
foregoing clause (i) solely as the result of an acquisition
of securities by the Company which, by reducing the number of
shares of Voting Securities outstanding, increases the
proportionate number of shares of Voting Securities beneficially
owned by any person in excess of 50% or more of the combined
voting power of all then outstanding Voting Securities;
provided, however, that if any person referred to
in this sentence shall thereafter become the beneficial owner of
any additional shares of Voting Securities (other than pursuant
to a stock split, stock dividend, or similar transaction or as a
result of an acquisition of securities directly from the
Company) and immediately thereafter beneficially owns in excess
of 50% of the combined voting power of all then outstanding
Voting Securities, then a Change of Control shall be
deemed to have occurred for purposes of the foregoing clause (i).
Section 16. GENERAL
PROVISIONS
(a) No Distribution; Compliance with Legal
Requirements. The Administrator may require
each person acquiring Stock pursuant to an Award to represent to
and agree with the Company in writing that such person is
acquiring the shares without a view to distribution thereof.
No shares of Stock shall be issued pursuant to an Award until
all applicable securities law and other legal and stock exchange
or similar requirements have been satisfied. The Administrator
may require the placing of such stop-orders and restrictive
legends on certificates for Stock and Awards as it deems
appropriate.
No Award under the Plan shall be a nonqualified deferred
compensation plan, as defined in Code Section 409A, unless
such Award meets in form and in operation the requirements of
Code Section 409A(a) (2), (3), and (4).
(b) Delivery of Stock
Certificates. Stock certificates to grantees
under this Plan shall be deemed delivered for all purposes when
the Company or a stock transfer agent of the Company shall have
mailed such certificates in the United States mail, addressed to
the grantee, at the grantees last known address on file
with the Company.
(c) Other Compensation Arrangements; No Employment
Rights. Nothing contained in this Plan shall
prevent the Board from adopting other or additional compensation
arrangements, including trusts, and such arrangements may be
either generally applicable or applicable only in specific
cases. The adoption of this Plan and the grant of Awards do not
confer upon any employee any right to continued employment with
the Company or any Subsidiary.
(d) Trading Policy
Restrictions. Option exercises and other
Awards under the Plan shall be subject to such Companys
insider trading policy, as in effect from time to time.
(e) Loans to Grantees. The Company
shall have the authority to make loans to grantees of Awards
hereunder (including to facilitate the purchase of shares) and
shall further have the authority to issue shares for promissory
notes hereunder.
(f) Designation of
Beneficiary. Each grantee to whom an Award
has been made under the Plan may designate a beneficiary or
beneficiaries to exercise any Award or receive any payment under
any Award
A-11
payable on or after the grantees death. Any such
designation shall be on a form provided for that purpose by the
Administrator and shall not be effective until received by the
Administrator. If no beneficiary has been designated by a
deceased grantee, or if the designated beneficiaries have
predeceased the grantee, the beneficiary shall be the
grantees estate.
Section 17. EFFECTIVE
DATE OF PLAN
This Plan shall become effective upon approval by the holders of
a majority of the shares of Stock of the Company present or
represented and entitled to vote at a meeting of stockholders at
which a quorum is present or by written consent of the
stockholders. Subject to such approval by the stockholders,
Stock Options and other Awards may be granted hereunder on and
after adoption of this Plan by the Board.
Section 18. GOVERNING
LAW
This Plan and all Awards and actions taken thereunder shall be
governed by, and construed in accordance with, the laws of the
State of Delaware, applied without regard to conflict of law
principles.
A-12
. C123456789 000004 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext
000000000.000000 ext MR A SAMPLE DESIGNATION (IF ANY) 000000000.000000 ext 000000000.000000 ext ADD
1 Electronic Voting Instructions ADD 2 ADD 3 You can vote by Internet or telephone! ADD 4 Available
24 hours a day, 7 days a week! ADD 5 Instead of mailing your proxy, you may choose one of the two
voting ADD 6 methods outlined below to vote your proxy. VALIDATION DETAILS ARE LOCATED BELOW IN THE
TITLE BAR. Proxies submitted by the Internet or telephone must be received by 1:00 a.m., Central
Time, on December 20, 2007. Vote by Internet Log on to the Internet and go to
www.investorvote.com Follow the steps outlined on the secured website. Vote by telephone Call
toll free 1-800-652-VOTE (8683) within the United States, Canada & Puerto Rico any time on a touch
tone telephone. There is NO CHARGE to you for the call. Using a black ink pen, mark your votes with
an X as shown in X Follow the instructions provided by the recorded message. this example. Please
do not write outside the designated areas. Special Meeting Proxy Card 123456 C0123456789 12345
3 IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND
RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. 3 + A Proposals The Board of
Directors recommends a vote FOR the following proposal. For Against Abstain 1. Approve an increase
to the number of shares of common In their discretion, the proxies are authorized to vote upon such
stock available for issuance under the Inverness Medical other business as may properly come before
the meeting. Innovations, Inc. 2001 Stock Option and Incentive Plan by 3,000,000, from 8,074,871 to
11,074,871. B Non-Voting Items Change of Address Please print new address below. C Authorized
Signatures This section must be completed for your vote to be counted. Date and Sign Below
Please sign this proxy exactly as names appear hereon. When shares are held by joint tenants, both
should sign. When signing as an attorney, executor, administrator, trustee or guardian, please give
full title as such. If a corporation, please sign in full corporate name by president or other
authorized officer. If a partnership, please sign in partnership by authorized person. Date
(mm/dd/yyyy) Please print date below. Signature 1 Please keep signature within the box.
Signature 2 Please keep signature within the box. C 1234567890 J N T MR A SAMPLE (THIS AREA IS
SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE
AND MR A SAMPLE AND NNNNNNN0 1 A V 0 1 5 6 8 4 1 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND +
<STOCK#> 00T2KB |
3 IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND
RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. 3 Proxy Inverness Medical
Innovations, Inc. 51 SAWYER ROAD, SUITE 200 WALTHAM, MASSACHUSETTS 02453 Proxy For Special Meeting
of Stockholders To Be Held December 20, 2007 This Proxy is Solicited on Behalf of the Board of
Directors The undersigned hereby appoints RON ZWANZIGER and JAY MCNAMARA, and each of them acting
singly, Proxies with full power of substitution in each of them, in the name, place and stead of
the undersigned, to vote all shares of the voting stock of Inverness Medical Innovations, Inc.
which the undersigned is entitled to vote at the Special Meeting of Stockholders of Inverness
Medical Innovations, Inc. to be held on December 20, 2007 at 11:00 A.M. at the Companys Corporate
Headquarters, 51 Sawyer Road, Suite 200, Waltham, MA 02453, or any adjournment or postponement
thereof, upon the matters set forth on the reverse side. THIS PROXY WILL BE VOTED IN ACCORDANCE
WITH THE INSTRUCTIONS GIVEN ON THE REVERSE SIDE; IF NO INSTRUCTIONS ARE GIVEN, THIS PROXY WILL BE
VOTED FOR EACH OF THE PROPOSALS LISTED ON THE REVERSE SIDE. (Continued and to be voted on reverse
side.) |